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Traditionally, cancer epidemiologists have investigated the causes of disease under the
premise that patients with a certain site of disease can be treated as a single entity. Then
risk factors associated with the disease are identified through case-control or cohort studies
for the disease as a whole. However, with the rise of molecular and genomic profiling, in
recent years biologic subtypes have increasingly been identified. Once subtypes are known,
it is natural to ask the question of whether they share a common etiology, or in fact arise
from distinct sets of risk factors, a concept known as etiologic heterogeneity. This disser-
tation seeks to evaluate methods for the study of etiologic heterogeneity in the context of
cancer research and with a focus on methods for case-control studies. First, a number of
existing regression-based methods for the study of etiologic heterogeneity in the context
of pre-defined subtypes are compared using a data example and simulation studies. This
work found that a standard polytomous logistic regression approach performs at least as
well as more complex methods, and is easy to implement in standard software. Next, simu-
lation studies investigate the statistical properties of an approach that combines the search
for the most etiologically distinct subtype solution from high dimensional tumor marker
data with estimation of risk factor effects. The method performs well when appropriate
up-front selection of tumor markers is performed, even when there is confounding structure
or high-dimensional noise. And finally, an application to a breast cancer case-control study
demonstrates the usefulness of the novel clustering approach to identify a more risk hetero-
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CHAPTER 1. INTRODUCTION 1
Chapter 1
Introduction
1.1 Introduction to etiologic heterogeneity
The basic goal of most epidemiologic research is to investigate the prevalence and cause
of disease. Traditionally, epidemiologists have organized this line of research under the
premise that patients with a certain disease share an underlying etiology, or cause. In
this framework, the disease is treated as a single entity, and investigators have sought to
identify risk factors that are associated with the disease using case-control or cohort study
designs. In the early 1990s epidemiologists began to focus attention on the possibility that
risk factors, particularly occupational exposures and environmental carcinogens, may lead
to biologically-distinct subtypes of disease with respect to individual somatic mutations
(see, for example, Taylor et al. (1994)). More recently attention has increasingly focused
on identifying subtypes of disease according to disease characteristics such as molecular
markers or pathologic features. This has been especially true in cancer research because of
the growing use of molecular and genomic profiling, which give researchers access to many
more ways in which to classify a tumor. It is now widely accepted that many cancers,
including but not limited to breast (Perou et al., 2000; Sorlie et al., 2001; Sotiriou et al.,
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2003; Gaudet et al., 2011), lung (Ahrendt et al., 2001; Riely et al., 2008; Marsit et al.,
2009), colorectal (Limsui et al., 2010; Ogino et al., 2011), ovarian (Merritt et al., 2013), and
endometrial (Brinton et al., 2013; Schildkraut et al., 2013) cancers, are comprised of specific
molecular subtypes. As these subtypes are identified, it is natural to ask the question of
whether they share a common etiology, or in fact arise from distinct sets of risk factors. The
concept of differing risk factors across subtypes of disease is known as etiologic heterogeneity.
1.2 Introduction to statistical methods
There are many challenges related to the study of etiologic heterogeneity, and statistical
methods are needed not only to detect the presence of heterogeneity, but also to quantify the
extent of that heterogeneity. One challenge is the possibly high dimension of the data, which
may include information from multiple molecular profiling platforms such as expression,
copy number, mutation, and methylation data. Further, as more evidence accumulates for
subtypes of cancers with distinct risk profiles according to known risk factors, it is natural
to ask whether undiscovered risk factors will also exhibit differential associations across
subtypes. An epidemiologic investigation of etiologic heterogeneity such as a case-control
study would naturally be subject to the constraints of smaller subtype sample sizes as
compared to the aggregate case group, as well as the prospect of false discovery due to the
increasing number of statistical comparisons being made. However, such investigation also
serves to benefit from a potentially larger effect size in at least one subtype and improved
risk prediction accuracy for all patients.
Before undergoing the task of addressing these and many other statistical challenges,
it is important to identify what advantage, if any, researchers stand to gain by considering
subtypes of disease as opposed to an aggregate case group. Begg and Zabor (2012) inves-
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tigated the statistical implications of these trade-offs in the choice between a traditional
case-control design versus one that further classifies cases into subtypes using a simulation
study to examine statistical power under various study design scenarios. This study found
that over a range of risk factor prevalences and overall case-control odds ratios, only modest
heterogeneity was needed before a study design that accounts for subtypes achieved equiva-
lent power to a traditional case-control approach that considers all cases in aggregate. This
result provides a practical motivation to pursue development of statistical methods for the
study of etiologic heterogeneity.
1.2.1 Traditional approach
Early investigations of etiologic heterogeneity relied on standard statistical methods. Typ-
ically, an investigator would have data on cases and controls. The cases would then be
divided into a small number of pre-determined subtypes. These subtypes could be based on
a single disease characteristic, or on combinations thereof. Then, associations with risk fac-
tors could be examined using polytomous logistic regression (Dubin and Pasternack, 1986).
Polytomous logistic regression allows for the simultaneous estimation of subtype-specific
regression parameters, and differences in risk factor effects across subtypes can be tested.
Data on subtypes from cohort studies can be similarly analyzed using competing risks re-
gression, where those who have not yet developed the disease at the end of follow-up are
censored, and the subtypes comprise each of the possible competing events.
Shortly thereafter, Begg and Zhang (1994) proposed that in fact all of the information
needed to test for etiologic heterogeneity is contained in the cases, so it is not necessary
to include data on controls. This is an important idea since often epidemiologists have
access to case series data, with no data on a control population, especially in hospital
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research settings. Polytomous logistic regression can still be used, but now one of the
subtypes is selected to serve as the reference group. Choice of reference subtype could
be determined based on sample size, as selecting the subtype with the largest sample size
as the reference group will produce the most stable estimates, or based on subject-area
interest. Regression parameters are more difficult to interpret in the case-only setting due
to the lack of a control group, as the control group allows for interpretations with respect
to the non-diseased population, but the resulting regression parameters still allow for tests
of differences in risk factor effects across subtypes.
These approaches have the advantage of being straightforward and easy to implement
and interpret. However, they become inefficient or impossible to implement as the number
of subgroups grows, and they do not provide direct information about the extent to which
subtypes are etiologically distinct. Furthermore, the subtypes must be pre-specified, and
subtype assignment occurs in isolation from the analysis of risk factors.
1.2.2 Recent advances
In recent years a number of new methods have been proposed, some of which are extensions
of the traditional approach and others that are more novel.
1.2.2.1 Approaches that require pre-specified subtypes
Chatterjee (2004) proposed a two-stage regression model to address the analytic issue of
having a potentially large number of subtypes that cannot be handled by standard polyto-
mous logistic regression techniques while simultaneously allowing an investigator to deter-
mine which disease characteristics play a role in defining the etiologically distinct subtypes.
Use of a second-stage model for the subtype-specific regression parameters of the first-
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stage polytomous logistic regression model reduces the dimensionality problem while also
providing a testing strategy for etiologic heterogeneity. Interaction effects can be flexibly
included in the second-stage model, though most of the time interest will be limited to the
case of first-order interaction effects, which imply an additive model such that the effect
of one disease characteristic does not depend on other disease characteristics. This model
leads to a conditional interpretation, such that the degree of etiologic heterogeneity with
respect to one disease characteristic is interpreted in the context of all of the other disease
characteristics being held constant.
For estimation of the custom two-stage model, Chatterjee (2004) suggests a semipara-
metric approach that leaves the intercept parameters completely unspecified and limits the
second-stage model to the regression parameters of interest. The reasons for this are two-
fold: 1) the intercept parameters themselves are not of scientific interest and 2) simulation
studies revealed that mis-specification of the intercept parameters can lead to substantial
bias in the regression parameters of interest. Estimation can be carried out using a proposed
pseudo-conditional-likelihood approach, which Chatterjee (2004) shows to be asymptotically
valid and computationally efficient in a simulation study; however, the estimation procedure
requires customized programming.
While the original two-stage modeling approach proposed by Chatterjee (2004) is ap-
propriate for case-control data, epidemiologic research is often conducted using data from
prospective cohort studies. Chatterjee et al. (2010) extended the earlier work by proposing
a two-stage modeling approach for use with data from cohort studies. Now the first-stage
model is a competing risks regression model rather than a polytomous logistic regression
model, and the second-stage model is the same as before. An additional extension of this
work was to the case of missing data. It is common in epidemiologic studies for there to
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be missing disease characteristic data, and the proposed estimation procedure can handle
missing data with a missing-at-random assumption through an extension of the estimating
equation approach of Goetghebeur and Ryan (1995). Similarly to the unspecified intercept
parameters in the case-control setting, the baseline hazard is unspecified. Chatterjee et al.
(2010) demonstrate the asymptotic unbiasedness of the estimator and also show through
a simulation study that the estimator performs well in most cases, even when the baseline
hazard is mis-specified. These methods focus on testing for the association between a single
risk factor and a single disease characteristic, when all other disease characteristics are held
constant.
Rosner et al. (2013) proposed a single-stage approach to examining the effect of risk
factors on disease characteristics while controlling for other disease characteristics. This
has traditionally been accomplished by creating subtypes based on all possible combinations
of the disease characteristics. However, as the number of disease characteristics available
for study grows, this becomes increasingly infeasible. A regression approach that assesses
interaction effects of risk factors with specific disease characteristics while controlling for
levels of other disease characteristics for use in the setting of cohort studies was proposed,
based on a variation of a cause-specific hazard model (Rosner et al., 2013). This method is
particularly appropriate when the assumption of independence of the effects of individual
disease characteristics on the baseline hazard does not hold, as it allows for incorporation
of interaction effects between individual disease characteristics, thus accounting for the
common problem of correlation between disease characteristics. Additionally, it has the
appeal of being implemented using standard software. This method contrasts with that
of Chatterjee et al. (2010) in that it does not imply independence of the effects of disease
characteristics on the baseline hazard and no custom estimation procedure is required.
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Similarly to the problem with polytomous logistic regression, the approach of Rosner
et al. (2013) can become computationally infeasible as the number of disease characteris-
tics defining the subtypes grows. In response, Wang et al. (2015) introduced a two-stage
version of the Rosner et al. (2013) method, with applications to cohort studies, nested
case-control studies, and unmatched case-control studies. For a cohort study or nested
case-control study, the first stage of the analysis uses a cause-specific hazards model. For
an unmatched case-control study, the first stage is instead a polytomous logistic regression
model. A second-stage analysis then allows one to test whether the association between
the risk factor of interest and each subtype differs according to the levels of the individ-
ual disease characteristics that comprise the subtypes. This fixed effects two-stage method
differs from that of Chatterjee et al. (2010) in the estimation approach rather than in the
intrinsic model setup. To account for additional heterogeneity that may not be captured by
the available disease characteristics, Wang et al. (2015) proposed an alternative approach
that incorporates a random intercept in the second-stage model to account for unmeasured
variance.
1.2.2.2 Approaches that search for the most heterogeneous subtypes
The methods described so far can be used when there are pre-defined disease characteris-
tics of interest. While this approach can tell you whether individual disease characteristics
demonstrate etiologic heterogeneity with respect to each individual risk factor, there is no
intrinsic way to quantify the overall degree of etiologic heterogeneity. To provide epidemio-
logic investigators with a method that could be used to search for the set of subtypes that
best explain etiologic heterogeneity, Begg et al. (2013) introduced a scalar heterogeneity
measure that can be used to compare candidate subtyping schemes based on their overall
CHAPTER 1. INTRODUCTION 8
degree of etiologic heterogeneity. The goal is to identify the set of subtypes that best ex-
plains the etiologic heterogeneity of the disease of interest by defining a measure of etiologic
heterogeneity. The strategy is based on the use of the coefficient of variation, which is a
measure of risk heterogeneity in the population. The proposed measure can be used to
compare different subtyping options and determine which option demonstrates the high-
est degree of etiologic heterogeneity. Once the optimal subtype solution is identified, then
traditional methods such as polytomous logistic regression can be used to investigate risk
factor effects. This method not only integrates the classification of cases into subtypes with
the examination of risk factor effects, but also provides a scalar measure of the extent to
which the subtypes are etiologically distinct with respect to the entire set of risk factors
simultaneously.
All of the preceding methods have used a regression framework to approach the study
of etiologic heterogeneity. Yu et al. (2015) proposed an approach to the study of etiologic
heterogeneity that alternatively uses binary recursive partitioning. The framework for this
method is that disease characteristics can be combined to form subtypes of disease. Subjects
are initially split into two groups. Then, at each split, one of the two terminal nodes is
selected for further splitting based on a “goodness-of-split” criteria. After all splits are
made, there is a set of candidate tree models, each of different size and complexity. The
terminal nodes of each candidate tree can then be considered as candidate subtypes, and
used as the outcome in polytomous logistic regression to accomplish effect estimation and
heterogeneity testing. Because the candidate trees have been selected based on a search of
the data for the best split, to avoid overoptimism Yu et al. (2015) propose a resampling-
based procedure to estimate the p-value for each candidate tree, where the risk factor of
interest is randomly permuted among subjects with the same observed covariates. Finally,
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the candidate tree with the smallest p-value is selected as the final definition for disease
subtyping. This approach provides a way to subtype cases in order to get a result that
maximizes etiologic heterogeneity by seeking to group cases into subtypes based on the
association between the risk factor of interest and a binary grouping of cases at each step.
This approach does not provide a way to quantify the extent of etiologic heterogeneity
according to the various candidate trees.
Whereas the approaches discussed so far assume that each patient belongs to only a
single subtype, Schildkraut et al. (2013) developed a method to examine the association
between molecular subtypes of ovarian cancer and patient demographics and epidemiologic
risk factors that allows for the possibility that membership in a subtype is not always rigid
and the tumor of each patient could have characteristics of more than one subtype. This
method is specifically motivated in cancer research by the increasing interest in intra-tumor
heterogeneity. The method was applied to identify subtypes of ovarian cancer using consen-
sus k-means clustering of gene expression data, and class prediction by k-nearest neighbors
and diagonal linear discriminate analysis, with k, the number of subtypes, determined by
the gap statistic (Tothill et al., 2008). Once the subtypes are determined, each case is
assigned a score for each subtype. The score is based on a weighted sum of the normalized
expression values for overexpressed probes in the subtype minus a weighted sum of the
normalized expression values for underexpressed probes in the subtype (Sfakianos et al.,
2013). High positive scores indicate that a case is likely to belong to that subtype whereas
low scores indicate that the case is likely not to belong to that subtype. The moderate pos-
itive correlations observed between some pairs of the six subtypes provide evidence that the
subtypes may not be mutually exclusive. The scores for each patient were then normalized,
and Schildkraut et al. (2013) applied multivariate response multiple regression models with
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unstructured covariance to assess the relationship between cancer risk factors and the iden-
tified molecular subtypes. This approach accounts for the correlation between scores for the
various subtypes from a single patient, and the unstructured covariance does not make any
assumptions about the form that correlation takes. Note that this is a case-only analysis,
and no controls or cancer-free participants are used. Testing for heterogeneity is conducted
by incorporating an interaction term for the subtypes by the risk factor of interest. A sig-
nificant interaction effect suggests that the risk factor is associated with score differently
depending on subtype whereas a non-significant interaction effect suggests that the effect
of the risk factor on score does not differ based on subtype. This approach is applicable
to situations where tumors are being classified into subtypes based on a single molecular
platform of information, rather than potentially multiple platforms or a combination of, for
example, gene expression data and histo-pathologic features.
1.3 Introduction to breast cancer heterogeneity
Breast cancer incidence in the United States remained stable from 2002-2011, at an average
age-standardized incidence of 122.8 cases per 100,000 women across all races, and breast
cancer remains one of the three leading cancer causes of death among women, together with
lung and colorectal cancers (Kohler et al., 2015). Breast tumors are biologically diverse, and
growing evidence over the past two decades supports the notion that breast cancer should
not be considered a single disease, but rather a group of diseases with distinct etiologies,
treatments, and prognoses. Numerous studies have used genomic data to classify breast
cancers into subtypes (Perou et al., 2000; Sorlie et al., 2001; Sotiriou et al., 2003), with
most classification schemes relying on hierarchical clustering of microarray data. The most
well-accepted subtyping scheme consists of four main subtypes of breast cancer, known as
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luminal A, luminal B, HER2-type, and basal-like subtypes, based on the PAM50 panel of
gene expression data (Sorlie et al., 2001). These subtypes are well-approximated by four
subtypes of breast cancer based solely on immunohistochemical (IHC) markers for estrogen
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor
2 (HER2). Luminal A tumors are defined as ER positive (+) and/or PR+, and HER2
negative (-), luminal B tumors are defined as ER+ and/or PR+ and HER2+, HER2-type
tumors are defined as ER- and PR- and HER2+, and basal-like tumors are triple negative,
defined as ER- and PR- and HER2-.
Numerous epidemiologic studies have investigated etiologic differences according to these
subtypes, primarily in the context of case-control studies (Millikan et al., 2008; Phipps
et al., 2008a,b; Yang et al., 2007). Differential risk factor effects have consistently been
identified, particularly with respect to body size, race, and hormonal risk factors such as
menopausal status. To date such analyses have been conducted in two distinct phases,
where identification of biologic subtypes of breast cancer occurs completely separately from
epidemiologic investigation of differential risk factor effects. As a result, it is unclear if the
most etiologically distinct subtypes of breast cancer have yet been identified.
1.4 Summary of introduction
This dissertation seeks to accomplish the following goals. Chapter 2 will explicate the
similarities and differences among regression-based statistical approaches to the study of
etiologic heterogeneity when there are pre-defined subtypes, including the standard polyto-
mous logistic regression method introduced in Section 1.2, and the methods of Chatterjee
(2004), Wang et al. (2015), and Rosner et al. (2013), introduced in Section 1.2.2.1. While
these approaches utilize different modeling strategies, they all aim to test hypotheses about
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associations between risk factors and subtypes or individual disease characteristics. It is im-
portant to understand the intricacies of how these methods compare, and to enumerate the
strengths and weaknesses of each. This will be accomplished through a data example and
simulation studies. Next, Chapter 3 will explore the validity of the method for identifying
optimally etiologicallly heterogeneous subtypes based on a scalar measure proposed by Begg
et al. (2013), introduced in Section 1.2.2.2. This method is of particular interest as it is the
only approach proposed to date the allows for quantification of the extent to which subtypes
are etiologically distinct. While this method has been used in a number of applications, to
date the statistical properties have not been rigorously studied. This will be accomplished
through the use of simulation studies to explore the ability of the method to identify the
truly etiologically heterogeneous subtypes, as quantified by the misclassification rate, under
a variety of scenarios, and to examine the usefulness of upfront dimension reduction of the
disease characteristic data. Finally, Chapter 4 will conduct a comprehensive application to
data from the Carolina Breast Cancer Study, a breast cancer case-control study with avail-
able gene expression data on a subset of the cases, using the optimal D clustering method.
Optimal subtype results will be compared to the traditional four classes of breast cancer
as defined by IHC markers and the PAM50 gene expression panel, which were introduced
in Section 1.3. This data application will elucidate the real-world methodologic challenges
confronted by epidemiologists when seeking to study etiologic heterogeneity in the context
of high dimensional disease characteristic data.
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Chapter 2
Comparison of existing methods?
The results of this chapter show that when the number of tumor markers is small
enough that the cross-classification of markers can be evaluated in the traditional
polytomous logistic regression framework, then the statistical properties are at
least as good as the more complex modeling approaches that have been proposed.
The potential advantage of more complex methods is in the ability to accommodate
multiple tumor markers in a model of reduced parametric dimension.
Epidemiologic questions of interest related to the study of etiologic heterogeneity may in-
clude 1) whether a risk factor of interest has the same effect across all subtypes of disease
and 2) whether risk factor effects differ across levels of each individual disease characteristic
by which the subtypes are defined. Early investigations of etiologic heterogeneity typically
divided cases into a small number of pre-determined subtypes, based on a single molecular
marker or pathologic feature, or on combinations thereof. Associations of specific sub-
types with risk factors could be examined using polytomous logistic regression (Dubin and
Pasternack, 1986). In recent years, however, a number of new statistical methods have been
?Note that the contents of this chapter have been published in Zabor and Begg, Statistics in Medicine
2017; 36:4050-60.
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proposed for the study of etiologic heterogeneity.
In this chapter, four distinct available methods are compared: polytomous logistic re-
gression; the two-stage meta-regression method proposed by Wang et al. (2015); the two-
stage regression with simultaneous estimation approach proposed by Chatterjee (2004); and
the stratified logistic regression approach of Rosner et al. (2013). These methods have very
distinctive parametric structures and it is not immediately straightforward how results using
the different methods align with each other. The goal is to reconcile the similarities among
the methods, and to evaluate their statistical properties. To accomplish this, a simplified
data example is employed to elucidate the interpretation of model parameters and available
hypothesis tests, and a simulation study is performed to assess bias in effect size, type I
error, and power.
2.1 Analytic framework
This chapter focuses solely on methods for the analysis of case-control data, though many
of the approaches discussed can be applied in the context of other study designs. And
because the simplified data example comes from breast cancer, throughout the disease
characteristics that combine to form subtypes are referred to as “tumor markers,” though
notably these methods are generalizable to disease contexts besides cancer. Let i index
study subjects, i = 1, . . . , N , let k index tumor markers, k = 1, . . . ,K, let m index disease
subtypes, m = 0, . . . ,M , where m = 0 denotes control subjects, and let p index risk
factors, p = 1, . . . , P . Initially, for simplicity, the focus is on a setting where there are
two binary tumor markers, each of which can be either positive (+) or negative (-). These
two tumor markers are cross-classified to form four disease subtypes (-/-, +/-, -/+, and
+/+). Additionally, for conceptual simplicity in the primary exposition and simulations,
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the investigation is limited to the case of a single binary risk factor of interest. Therefore,
the setting explored here has tumor markers k = 1, 2, disease subtypes m = 1, 2, 3, 4, and
risk factor p = 1.
The first epidemiologic question of interest to be addressed is whether the risk factor of
interest has the same effect across all subtypes of disease. This is frequently the primary
question of interest in an investigation of etiologic heterogeneity and allows one to determine
whether the risk factor of interest is associated with specific subtypes of disease. From each
of the available methods, the parameters βpm can be obtained, which represent the log
odds ratio for a one-unit change in risk factor p for subtype m disease versus controls.
In the case of four subtypes and one binary risk factor, there are four such log odds ratios
β11, β12, β13, and β14 (Table 2.1). Thus a test of the hypothesis H0β : β11 = β12 = β13 = β14
is of interest. A second epidemiologic question of specific interest is whether the risk factor
effect differs across levels of each individual tumor marker. This question allows one to
evaluate whether a specific tumor marker is in part responsible for observed differences in
log odds ratios of the risk factor across the subtypes. To answer this question, estimates
of parameters γpk are obtained, each of which represents the ratio of the log odds ratios
for the risk factor defined by different levels of the kth tumor marker when each level of
the other tumor markers is held constant. In the case of two binary tumor markers and a
single binary risk factor, γ11 and γ12 are obtained (Table 2.1). Then this question can be
addressed with tests of the hypotheses H0γ11 : γ11 = 0 and H0γ12 : γ12 = 0.
This chapter addresses how each of the four methods under consideration can be con-
structed to address these two epidemiologic questions, and compares the statistical prop-
erties of the methods. Throughout, it is important to keep in mind the original purpose
of each of the four methods. Polytomous logistic regression is constructed in such a way
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Table 2.1: Interpretation of model parameters
Does the risk factor effect differ with respect to subtypes?
Parameter Interpretation
β11 log odds ratio for subtype m = 1 vs controls
β12 log odds ratio for subtype m = 2 vs controls
β13 log odds ratio for subtype m = 3 vs controls
β14 log odds ratio for subtype m = 4 vs controls
Does the risk factor effect differ with respect to tumor markers?
Parameter Interpretation
γ11 average of differences in log odds ratios when tumor marker k = 1
is + vs - and k = 2 is fixed
γ12 average of differences in log odds ratios when tumor marker k = 2
is + vs - and k = 1 is fixed
as to naturally address the question of whether risk factor effects differ across subtypes
of disease. The βpm parameters are estimated directly in polytomous logistic regression.
Section 2.2.1 shows that the γpk parameters can then be obtained indirectly as a linear
combination of the estimated βpm parameters. Conversely, the two-stage regression with
simultaneous estimation approach of Chatterjee (2004) and the stratified logistic regression
approach of Rosner et al. (2013) were originally proposed to address the question of whether
risk factor effects differ across levels of each individual tumor marker. As such, the γpk pa-
rameters are estimated directly. Both methods also allow for inclusion of interaction effects
between individual tumor markers. Sections 2.2.3 and 2.2.4 show that when all first-order
interaction terms are included in the model, the βpm parameters can be obtained indirectly
as a linear combination of the estimated γpk parameters. The two-stage meta-regression
approach of Wang et al. (2015) was specifically proposed to address both the question of
whether risk factor effects differ across subtypes of disease and the question of whether risk
factor effects differ across levels of each individual tumor marker. In this approach the βpm
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parameters are directly estimated in the first-stage model and then the γpk parameters are
directly estimated in the second-stage model. Details of model specification and estimation
for each of the four methods follow in Section 2.2.
2.2 Methods
This section presents details of the estimation of model parameters and the hypothesis
testing procedure for each approach.
2.2.1 Polytomous logistic regression
Polytomous logistic regression allows for the simultaneous estimation of subtype-specific
regression parameters. Let Yi denote the disease status for subject i such that Yi = 0 for a
non-diseased control subject and Yi = m for a subject with disease subtype m. X1i denotes
the value of risk factor p = 1 for subject i. Then a polytomous logistic regression model is
specified as
Pr(Yi = m|X1i) = exp(β0m + β1mX1i)
1 +
∑4
m=1 exp(β0m + β1mX1i)
,m = 1, 2, 3, 4 (2.1)
where β0m is the intercept parameter for the mth disease subtype. To evaluate whether the
risk factor has the same effect across all subtypes of disease a Wald test of the hypothesis
H0β : β11 = β12 = β13 = β14 is performed.
Defining wkm as the level of the kth tumor marker corresponding to the mth disease
subtype, a linearly transformed set of parameters can be created using
βjm = γj0 + γj1w1m + γj2w2m + γj12w1mw2m (2.2)
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for j = 0, 1. It follows that estimates of the γpk parameters associated with the individual
tumor marker effects in the case of m = 4 disease subtypes can be obtained as
γ11 =
(β12 − β11) + (β14 − β13)
2
and γ12 =
(β13 − β11) + (β14 − β12)
2
.
Note that while here the case is limited to m = 4 disease subtypes formed by k = 2
tumor markers, this transformation is generalizable. Thus tests addressing the second
set of questions, whether risk factor effects differ across levels of each individual tumor
marker, can be accomplished using Wald tests of H0γ11 : β12 − β11 + β14 − β13 = 0 and
H0γ12 : β13 − β11 + β14 − β12 = 0.
It is of interest to note that when data are not available on control subjects, the test
for etiologic heterogeneity can be obtained using a case-only polytomous logistic regression
model (Begg and Zhang, 1994). In the polytomous logistic regression model one of the four
subtypes must be selected to serve as the reference group. Because there is no data on
controls, the main effects of the individual tumor markers cannot be determined, so case-
only polytomous logistic regression cannot test whether the effect of a risk factor differs
across levels of each individual tumor marker. As this method produces almost identical
results to those from polytomous logistic regression with regard to the question of whether
a risk factor of interest has the same effect across all subtypes of disease, it will not be
investigated in further detail.
2.2.2 Two-stage meta-regression
The method of Wang et al. (2015) is a two-stage approach. As noted in Section 2.1, this
method was specifically proposed to address both the question of whether risk factor effects
differ across disease subtypes and the question of whether risk factor effects differ across
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levels of each individual tumor marker. The first stage of the analysis uses the previously
introduced polytomous logistic regression model (Equation 2.1). Thus the test of whether
the risk factor has the same effect across all four subtypes of disease is identical to the one
used in Section 2.2.1 above. A second-stage analysis is then employed to directly estimate
the parameters γ10, γ11, and γ12 for risk factor p = 1 using a weighted linear regression
model,
βˆ1m = γ10 + γ11w1m + γ12w2m + e1m, (2.3)
where βˆ1m is the estimated log odds ratio of subtype m versus controls for risk factor
p = 1 from the polytomous logistic regression model and e1m is within study sampling
error such that V ar(e1m) = V̂ ar(βˆ1m). Wald tests of the hypotheses H0γ11 : γ11 = 0 and
H0γ12 : γ12 = 0 are used to test whether the risk factor effect differs across levels of each
individual tumor marker.
Wang et al. (2015) also propose that the second stage model in Equation 2.3 can be
extended to include a random effect, which could capture variance between subtypes not
explained by the included tumor markers. Alternatively, the second stage model in Equa-
tion 2.3 can incorporate interaction terms between the individual tumor markers in order
to evaluate whether the effect of the risk factor associated with one tumor marker actu-
ally depends on the level of another tumor marker. These alternative second-stage model
specifications are not examined in depth, but may in fact prove more appropriate in certain
study settings.
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2.2.3 Two-stage regression with simultaneous estimation
The method of Chatterjee (2004) is also a two-stage approach with a similar model struc-
ture. However, unlike the preceding two-stage meta-regression method (Wang et al., 2015),
this approach specifies a joint likelihood and uses a maximum likelihood estimation pro-
cedure to simultaneously estimate the first-stage and second-stage regression parameters.
When the total number of disease subtypes is moderate, maximum likelihood estimation
of the two-stage model is relatively straightforward, though a pseudo-conditional likelihood
estimation method is also proposed for the case when the number of disease subtypes is large
(Chatterjee, 2004). This method was proposed in order to address the question of whether
risk factor effects differ across levels of each individual tumor marker. The first-stage model
is the polytomous logistic regression model defined in Equation 2.1. The second-stage model
to address the question of whether the effect of risk factor p = 1 differs across levels of each
individual tumor marker can be constructed as,
β1m = γ10 + γ11w1m + γ12w2m. (2.4)
In this framework it is of interest to test the independent effect of each tumor marker
when all other tumor markers are held constant. Score tests of the hypotheses H0γ11 : γ11 =
0 and H0γ12 : γ12 = 0 can test whether the risk factor effect differs across levels of each
individual tumor marker.
However, this model also allows for inclusion of interaction effects between individual
tumor markers. If all interaction effects are incorporated then
β1m = γ10 + γ11w1m + γ12w2m + γ112w1mw2m, (2.5)
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would be utilized, where γpk1k2 is a measure of the interaction effect between the k1th and
k2th tumor markers with respect to the pth risk factor. Note that this is equivalent to
Equation 2.2 for the case of j = 1. Analogous to Section 2.2.1, in this setting the βpm
parameter estimates can be obtained based on linear combinations of the γpk parameter
estimates using the fact that β11 = γ10, β12 = γ10+γ11, β13 = γ10+γ12, and β14 = γ10+γ11+
γ12 + γ112. Thus a test of whether the risk factor has the same effect across all four disease
subtypes can be conducted by a Wald test of the hypothesis H0β : γ11 = γ12 = γ112 = 0.
One could also test the hypothesis H0γpk1k2
: γ112 = 0 in order to determine whether the
effect of risk factor p = 1 associated with tumor marker k = 1 actually depends on the level
of tumor marker k = 2.
2.2.4 Stratified logistic regression
As an alternative to a two-stage approach, Rosner et al. (2013) proposed a single-stage
regression method. This method was originally designed to address the question of whether
risk factor effects differ across levels of each individual tumor marker using a computational
structure for which software is readily available. Let Zmi indicate the disease status for
subject i specific to subtype m disease such that
Zmi =

1 if Yi = m
0 if Yi 6= m,
for m = 1, . . . ,M . In control subjects Zmi = 0 for all m. In contrast to all previously dis-
cussed methods, here a data augmentation approach is used, such that each case contributes
m correlated outcomes, one for each combination of tumor markers, i.e. each disease sub-
type m (Rosner et al., 2013). This approach was originally designed for use in the setting of
cohort studies and was implemented using a Cox regression model stratified by the disease
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subtype. However, using the fact that a stratified Cox regression model is equivalent to a
stratified logistic regression model (Gail et al., 1981), also known as a conditional logistic
regression model, the method can easily be applied in the setting of a case-control study
when time is constant for all included subjects and data are structured as described. The
same data augmentation approach is used, and the logistic regression model is stratified by
disease subtype.
To address the question of whether a risk factor of interest, X1i, has the same effect
across levels of each individual tumor marker, the stratified logistic regression model can
be specified as
Pr(Zmi = 1|X1i,wm) = exp (αm + γ10X1i + γ11X1iw1m + γ12X1iw2m)
1 + exp (αm + γ10X1i + γ11X1iw1m + γ12X1iw2m)
, (2.6)
where wm = {w1m, . . . , wkm} is the vector of tumor markers for the mth subtype and αm is
the stratum-specific intercept term, which cancels out in the conditional likelihood (Breslow
and Day, 1980). This model can be used to test whether the risk factor effect differs across
levels of each individual tumor marker using Wald tests of the hypotheses H0γ11 : γ11 = 0
and H0γ12 : γ12 = 0.
The stratified logistic regression approach of Rosner et al. (2013) also allows for inclusion
of interaction effects between individual tumor markers. When all interaction effects are
included, the model
Pr(Zmi = 1|X1i,wm) = exp (αm + γ10X1i + γ11X1iw1m + γ12X1iw2m + γ112X1iw1mw2m)
1 + exp (αm + γ10X1i + γ11X1iw1m + γ12X1iw2m + γ112X1iw1mw2m)
(2.7)
is obtained, and as in Section 2.2.3 the βpm parameters can be obtained indirectly as a
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linear combination of the γpk parameters to test whether the risk factor has the same effect
across all four disease subtypes.
2.2.5 Software
All statistical analyses were conducted using R software (R Core Team, 2018). For poly-
tomous logistic regression, the multinom function from the nnet package (Venables and
Ripley, 2002) was used for estimation and the wald.test function from the aod package
(Lesnoff et al., 2012) was used for significance testing. For the second-stage model in the two-
stage meta-regression method of Wang et al. (2015), the rma.mv function from the metafor
package (Viechtbauer, 2010) was used for estimation and significance testing. Estimation
and significance testing for the two-stage regression with simultaneous estimation method
of Chatterjee (2004) was conducted using an R function provided by the authors, except in
the case of the test of H0β , which was conducted using the wald.test function from the aod
package (Lesnoff et al., 2012). Finally, following data augmentation, the clogit function
from the survival package (Therneau, 2015; Terry M. Therneau and Patricia M. Gramb-
sch, 2000) was used for estimation and testing for the stratified logistic regression method
of Rosner et al. (2013). For all methods besides that of Chatterjee (2004), other standard
software packages that support the underlying statistical models could be used. However
all require transformation of the results from one parametric configuration to another and
use the parameter estimates and variance-covariance matrices for hypothesis testing.
2.3 Data example
Data from a previous study that combined two large breast cancer case-control studies, the
Cancer and Steroid Hormone (CASH) study and the Womens’ Contraceptive and Repro-
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ductive Experiences (CARE) study, leading to a total of 984 cases and a corresponding 1592
controls, are used to illustrate the methods (Begg et al., 2013). The goal in this section is
not to conduct a detailed analysis of etiologic heterogeneity in breast cancer. Instead, the
focus is on a simplified strategy that addresses the etiologic heterogeneity of breast cancer
classified into subtypes described by estrogen receptor (ER) and progesterone receptor (PR)
status from the perspective of a single risk factor, oral contraceptive (OC) use. The purpose
is simply to contrast the various modeling strategies.
The primary results from the four methods are presented in Table 2.2. The top portion
of the table contains results relevant to the question of whether OC use has the same
effect across the four disease subtypes. This question is addressed with Equation 2.1 for
polytomous logistic regression and the method of Wang et al. (2015), Equation 2.5 for the
method of Chatterjee (2004), and Equation 2.7 for the method of Rosner et al. (2013). All
methods lead to rejection of the null hypothesis (all p-values < 0.05), so regardless of the
method the conclusion is that the effect of OC use differs across the four disease subtypes.
Of note the parameter estimates for polytomous logistic regression, the method of Wang et
al. (2015), and the method of Chatterjee (2004) are practically identical. This is expected
as the first-stage model for the method of Wang et al. (2015) is simply the polytomous
logistic regression model, and when all first order interaction effects are included in the
method of Chatterjee (2004) and maximum likelihood estimation is used, this model should
produce results that are nearly identical to those from the polytmous logistic regression
model. Finally, note that there are some small differences between the parameter estimates
from the method of Rosner et al. (2013) as compared to the other three methods, in that
the parameter estimates are all less positive in magnitude.
The lower portion of Table 2.2 displays results related to the questions of whether
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Table 2.2: Results of data example comparing existing methods
Does the risk factor effect differ with respect to subtypes?
Method Subtype Parameter Estimate p-value
Polytomous1



















Does the risk factor effect differ with respect to tumor markers?
Method Tumor marker Parameter Estimate p-value
Polytomous1
ER γ11 -0.30 0.046
PR γ12 0.02 0.887
Wang2
ER γ11 -0.33 0.031
PR γ12 0.05 0.731
Chatterjee3
ER γ11 -0.33 0.028
PR γ12 0.05 0.719
Rosner4
ER γ11 -0.34 0.024
PR γ12 0.05 0.739
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
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the effect of OC use differs across levels of ER status when PR status is held constant,
and whether the effect of OC use differs across levels of PR status when ER status is
held constant. These questions are addressed with Equation 2.1 for polytomous logistic
regression, Equation 2.3 for the method of Wang et al. (2015), Equation 2.4 for the method
of Chatterjee (2004), and Equation 2.6 for the method of Rosner et al. (2013). Again, the
parameter estimates and p-values are similar. Regardless of the method, the conclusion is
that the effect of OC use on breast cancer risk differs by ER status, but the effect of OC
use on breast cancer risk does not differ by PR status.
2.4 Simulation study
The simulation study is conducted using a similar framework to the data example, with
four disease subtypes formed by cross-classification of two tumor markers as described in
Section 2.1. There is a single binary risk factor of interest, with a prevalence among control
subjects of q = 0.3. Each simulation uses 1000 controls and 1000 cases, with the cases
divided equally among the four disease subtypes. The true regression coefficients are fixed
at β1m for subtype m disease, m = 1, 2, 3, 4. Risk factor data are randomly generated
for each subject with disease subtype m from a binomial distribution with probability
exp(qβ1m)/[1+exp(qβ1m)] and for each control subject with probability exp(q)/[1+exp(q)].
For each simulation setting, 1000 simulated data sets are generated.
To address the question of whether the risk factor effect differs across the disease sub-
types, the simulation study employs Equation 2.1 for polytomous logistic regression and
the method of Wang et al. (2015), Equation 2.5 for the method of Chatterjee (2004), and
Equation 2.7 for the method of Rosner et al. (2013). To address the question of whether
the risk factor effect differs across levels of each individual tumor marker, the simulation
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study uses Equation 2.1 for polytomous logistic regression, Equation 2.3 for the method of
Wang et al. (2015), Equation 2.4 for the method of Chatterjee (2004), and Equation 2.6 for
the method of Rosner et al. (2013).
It is important to note that some of the simulation settings imply an interaction effect
between the individual tumor markers whereas some of the simulation settings imply a
main effects model with no interaction effect. When there is no interaction between the
individual tumor markers, i.e. when γ112 = 0, then β14 = β12 + β13 − β11 and a test of
whether the risk factor effect differs across the disease subtypes can be conducted with
a test of H0β : γ11 = γ12 = 0. In settings where there is truly no interaction effect,
the method of Chatterjee (2004) is explored using both Equation 2.5 and Equation 2.4 to
determine whether there is an efficiency gain from using a model that does not incorporate
an interaction effect as compared to a model that does.
2.4.1 Data simulated under the null hypothesis
The first set of simulations is conducted under the null hypothesis for the question of whether
the risk factor effect differs across the four disease subtypes, and under the null hypothesis
for the question of whether the risk factor effect differs across levels of each individual
tumor marker. Set β11 = β12 = β13 = β14 = 0.1 and therefore γ11 = γ12 = 0. Equivalent
disease subtype effects such as this imply no interaction effect between the individual tumor
markers. For the question of whether the risk factor effect differs across the four disease
subtypes, the size of the test is 0.051 for polytomous logistic regression, the method of
Wang et al. (2015), and the method of Chatterjee (2004) whereas the method of Rosner et
al. (2013) has an inflated type I error of 0.089 (Table 2.3, upper portion). The biases in
parameter estimates are small for all methods except that of Rosner et al. (2013). When the
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main effects model of Chatterjee (2004) is applied using Equation 2.4, similarly small biases
of −0.000, −0.004, −0.001, and −0.006 are found for β11, β12, β13, and β14, respectively,
but there is a slightly inflated type I error of 0.068.
For the question of whether the risk factor effect differs across levels of each individual
tumor marker, polytomous logistic regression and the method of Chatterjee (2004) have very
similar type I errors for γ11 of 0.063 and for γ12 of 0.051 and 0.050, respectively (Table 2.3,
lower portion). The method of Wang et al. (2015) has lower type I errors, 0.037 and 0.031
for testing γ11 and γ12, respectively; conversely, the method of Rosner et al. (2013) has
inflated type I errors of 0.077 and 0.073. In this setting all methods produce parameter
estimates with comparably small biases.
2.4.2 Data simulated under the alternative hypothesis
The second set of simulations is conducted under the alternative hypothesis for the question
of whether the risk factor effect differs across the four disease subtypes, and under the
alternative hypothesis for the question of whether the risk factor effect differs across levels
of each individual tumor marker. Here let β11 = 0.2, β12 = β13 = 0.3, and β14 = 0.8 so
that γ11 = γ12 = 0.3. For the question of whether the effect of the risk factor differs across
the four subtypes, polytomous logistic regression, the method of Wang et al. (2015) and
the method of Chatterjee (2004) all have power of 0.822 whereas the method of Rosner et
al. (2013) has higher power of 0.862 (Table 2.3, upper portion). However, recall that the
method of Rosner et al. (2013) had higher type I error than the other methods, and so
calibration is needed to truly compare the signal detection srengths of the methods. While
biases are generally very small for most methods, there is substantial bias in parameter
estimates for the method of Rosner et al. (2013).
CHAPTER 2. COMPARISON OF EXISTING METHODS 29
Table 2.3: Results of simulation study comparing existing methods
Does the risk factor effect differ with respect to subtypes?
Null hypothesis Alternative hypothesis
Method Parameter Truth Bias Type I error Truth Bias Power
Polytomous1
β11 0.1 -0.000 0.051 0.2 -0.001 0.822
β12 0.1 -0.004 0.3 -0.006
β13 0.1 -0.001 0.3 -0.002
β14 0.1 -0.007 0.8 -0.007
Wang2
β11 0.1 -0.000 0.051 0.2 -0.001 0.822
β12 0.1 -0.004 0.3 -0.006
β13 0.1 -0.001 0.3 -0.002
β14 0.1 -0.007 0.8 -0.007
Chatterjee3
β11 0.1 -0.000 0.051 0.2 -0.001 0.822
β12 0.1 -0.004 0.3 -0.006
β13 0.1 -0.001 0.3 -0.002
β14 0.1 -0.007 0.8 -0.007
Rosner4
β11 0.1 0.047 0.089 0.2 0.190 0.862
β12 0.1 0.043 0.3 0.178
β13 0.1 0.046 0.3 0.182
β14 0.1 0.040 0.8 0.146
Does the risk factor effect differ with respect to tumor markers?
Null hypothesis Alternative hypothesis
Method Parameter Truth Bias Type I error Truth Bias Power
Polytomous1
γ11 0.0 -0.005 0.063 0.3 -0.005 0.589
γ12 0.0 -0.001 0.051 0.3 -0.001 0.599
Wang2
γ11 0.0 -0.005 0.037 0.3 0.005 0.483
γ12 0.0 -0.001 0.031 0.3 0.010 0.475
Chatterjee3
γ11 0.0 -0.005 0.063 0.3 0.006 0.560
γ12 0.0 -0.001 0.050 0.3 0.010 0.572
Rosner4
γ11 0.0 -0.005 0.077 0.3 -0.012 0.605
γ12 0.0 -0.001 0.073 0.3 -0.008 0.624
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
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For the question of whether the risk factor effect differs across levels of each individual
tumor marker, polytomous logistic regression and the method of Chatterjee (2004) again
have similar power (Table 2.3, lower portion). The method of Wang et al. (2015) has lower
power whereas the method of Rosner et al. (2013) has slightly higher power. However,
again recall that the method of Rosner et al. (2013) had inflated type I error. All methods
produce parameter estimates with small biases.
The following was done in order to compare the power of the methods in a calibrated
manner. First the effect size was varied by fixing β11 = 0.2 and β12 = β13 = 0.3, and
incrementally increasing β14 from 0.3 to 0.9. This allowed for determination of how large
the subtype four effect size, β14, needs to be in order to achieve various levels of power
to address whether the risk factor effect differs across the four disease subtypes. The
comparison was calibrated by ranking the simulated p-values under the null hypothesis and
choosing the critical value that ensured the test size was exactly 0.05, then this critical value
was used to determine power. Figure 2.1A shows the resulting power curves for the different
methods. After calibration of type I error, the four methods have indistinguishable power.
Note that one of these cases, when β14 = 0.4, implies no interaction effect between the
individual tumor markers. Whereas the calibrated power using Chatterjee’s Equation 2.5
results in a power of 0.122 in this setting, Equation 2.4 results in slightly lower calibrated
power of 0.119.
The power to address whether the risk factor effect differs across levels of each individual
tumor marker is similarly compared. Figure 2.1B shows the power to detect an effect for
γ1k. The results are similar across the four methods.
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Figure 2.1: Log odds ratio required to achieve various levels of power when type I error
is calibrated to α = 0.05 for (A) β14 to address whether risk factor effects differ across
subtypes, and (B) γ1k to address whether risk factor effects differ across levels of each
individual tumor marker.
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Table 2.4: Type I error for different risk factor prevalences q and true effect sizes β1m with
M = 4 disease subtypes formed by K = 2 individual tumor markers
q 0.3 0.6
β1m 0 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
Does the risk factor effect differ with respect to subtypes?
Polytomous1 0.052 0.051 0.060 0.055 0.054 0.055 0.054 0.047 0.051 0.046
Wang2 0.052 0.051 0.060 0.055 0.054 0.055 0.054 0.047 0.051 0.046
Chatterjee3 0.052 0.051 0.060 0.055 0.054 0.055 0.054 0.047 0.051 0.046
Rosner4 0.093 0.089 0.077 0.086 0.082 0.088 0.084 0.076 0.072 0.076
Does the risk factor effect differ with respect to tumor marker 1 (γ11)?
Polytomous1 0.064 0.063 0.056 0.057 0.058 0.057 0.058 0.051 0.042 0.045
Wang2 0.035 0.037 0.037 0.033 0.033 0.033 0.032 0.025 0.022 0.028
Chatterjee3 0.064 0.063 0.056 0.057 0.058 0.057 0.058 0.051 0.043 0.047
Rosner4 0.079 0.077 0.068 0.079 0.074 0.079 0.074 0.069 0.063 0.060
Does the risk factor effect differ with respect to tumor marker 2 (γ12)?
Polytomous1 0.057 0.051 0.055 0.058 0.049 0.059 0.049 0.048 0.044 0.052
Wang2 0.031 0.031 0.030 0.030 0.032 0.030 0.030 0.027 0.031 0.034
Chatterjee3 0.057 0.050 0.055 0.058 0.046 0.058 0.046 0.047 0.046 0.052
Rosner4 0.073 0.073 0.067 0.070 0.062 0.071 0.063 0.057 0.062 0.063
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
2.4.3 Data simulated under different configurations
Sensitivity analyses are conducted in order to further elucidate the statistical properties of
the four methods for the study of etiologic heterogeneity.
First, the sensitivity of the results in Sections 2.4.1 and 2.4.2 to the prevalence of the
risk factor are explored. Additional simulations were conducted for the case of four disease
subtypes and a single binary risk factor, with data generated as described at the beginning
of Section 2.4 using 1000 controls and 1000 cases. For each setting, 1000 simulated data
sets are generated. Here settings where the risk factor prevalence is q = 0.3 or q = 0.6 are
separately investigated. Data are first generated under the null hypothesis, and the true
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common regression coefficients (β11 = β12 = β13 = β14) are each fixed at 0, 0.1, 0.2, 0.3,
and 0.4. Results are presented in Table 2.4, with a similar pattern of results to the null
case presented in Table 2.3, which corresponds to risk factor prevalence q = 0.3 and true
common regression coefficients fixed at 0.1. Polytomous logistic regression and the methods
of Chatterjee (2004) and Wang et al. (2015) perform similarly with respect to type I error for
the test of H0β whereas the method of Rosner et al. (2013) is anti-conservative. Polytomous
logistic regression and the method of Chatterjee (2004) perform similarly with respect to
type I error for the tests of H0γ11 and H0γ12 whereas the method of Wang et al. (2015) is
conservative and the method of Rosner et al. (2013) is again anti-conservative. Data are
next generated under the alternative hypothesis. For each of the two risk factor prevalences,
three alternative scenarios are investigated, with true values for {β11, β12, β13} fixed at
{0.2, 0.25, 0.25}, {0.2, 0.3, 0.3}, and {0.2, 0.4, 0.4} and values of β14 ranging from 0.25 to
0.85, 0.3 to 0.9 and 0.4 to 1.0, respectively. Power was calibrated for all results as described
in Section 2.4.2. Results are presented in Figure 2.2 for β14 and Figure 2.3 for γ1k. In
all configurations of parametric values and risk factor prevalences, the pattern of results
is in line with those presented in Figure 1, such that all methods have similar power after
calibration for differences in type I error.
Next, the methods other than polymotomous logistic regression were created to accom-
modate multiple tumor factors, and thus have the capacity to take advantage of dimension
reduction. A limited exploration of the expansion of the number of tumor markers to K = 4
was conducted, whereby there are M = 16 subtypes that must be evaluated separately in
the logistic regression model. Data are generated for sixteen disease subtypes formed by
cross-classification of four binary tumor markers as described at the start of Section 2.4.
Again there is a single binary risk factor, and the settings where the risk factor prevalence
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Figure 2.2: Log odds ratio required to achieve various levels of power when type I error is
calibrated to α = 0.05 to address whether risk factor effects differ across M = 4 disease
subtypes
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Figure 2.3: Log odds ratio required to achieve various levels of power when type I error is
calibrated to α = 0.05 to address whether risk factor effects differ across each of the K = 2
individual tumor markers that form M = 4 disease subtypes
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is q = 0.3 or q = 0.6 are separately investigated. For each simulation setting, 500 simulated
data sets were generated using 1008 controls and 1008 cases to allow for equal subdivision of
cases into M = 16 subtypes. Data are first generated under the null hypothesis, and the true
common regression coefficients (β11 = β12 = · · · = β1(16)) are each fixed at 0.05, 0.1, 0.15,
and 0.2. Results are presented in Table 2.5. A similar pattern of results as in the case of
M = 4 subtypes was seen. Data are next generated under the alternative hypothesis. For
each of the two risk factor prevalences, three alternative scenarios are investigated, with
true values β1m = {0.2, 0.4, 0.4, 0.4, 0.4, 0.6, 0.6, 0.6, 0.6, 0.6, 0.6, 0.8, 0.8, 0.8, 0.8, 1.0}, β1m =
{0.2, 0.4, 0.4, 0.4, 0.4, 0.8, 0.8, 0.8, 0.8, 0.8, 0.8, 1.2, 1.2, 1.2, 1.2, 1.2}, and β1m = {0.2, 0.4, 0.4,
0.4, 0.4, 0.8, 0.8, 0.8, 0.8, 0.8, 0.8, 1.2, 1.2, 1.2, 1.2, 1.4}. Results are presented in Table 2.6.
Even as the number of subtypes increases to sixteen, a similar pattern of results is seen as
in the setting of four disease subtypes.
Finally, to investigate the setting where more than one risk factor is included, a data
example is conducted using the same data and subtypes described in Section 2.3 and in-
corporating a variety of continuous and binary risk factors of relevance to breast cancer
risk (Begg et al., 2013). Results are presented in Tables 2.7 and 2.8. The interpretation of
each risk factor must now be made in the context of adjustment for all other risk factors.
Across all risk factors, for the question of whether risk factor effects differ across disease
subtypes, polytomous logistic regression and the methods of Chatterjee (2004) and Wang
et al. (2015) result in similar parameter estimates and p-values whereas results from the
method of Rosner et al. (2013) differ slightly from the other methods. It is of interest to note
that in the context of a multivariable data analysis, the effect of oral contraceptive use is no
longer significantly different across disease subtypes (Table 2.7) whereas in the simplified
data example in Table 2.2, where only oral contraceptive use was included in the model,
CHAPTER 2. COMPARISON OF EXISTING METHODS 37
Table 2.5: Type I error for different risk factor prevalences q and true effect sizes β1m with
M = 16 disease subtypes formed by K = 4 individual tumor markers
q 0.3 0.6
β1m 0.05 0.1 0.15 0.2 0.05 0.1 0.15 0.2
Does the risk factor effect differ with respect to subtypes?
Polytomous1 0.052 0.050 0.038 0.034 0.036 0.028 0.030 0.044
Wang2 0.052 0.050 0.038 0.034 0.036 0.028 0.030 0.044
Chatterjee2 0.052 0.050 0.038 0.034 0.036 0.028 0.030 0.044
Rosner4 0.060 0.058 0.050 0.046 0.048 0.036 0.046 0.052
Does the risk factor effect differ with respect to tumor marker 1 (γ11)?
Polytomous1 0.060 0.054 0.040 0.032 0.050 0.054 0.040 0.042
Wang2 0.050 0.042 0.032 0.032 0.042 0.032 0.028 0.034
Chatterjee3 0.058 0.052 0.040 0.032 0.048 0.050 0.042 0.040
Rosner4 0.060 0.058 0.046 0.034 0.054 0.056 0.042 0.040
Does the risk factor effect differ with respect to tumor marker 2 (γ12)?
Polytomous1 0.044 0.052 0.050 0.042 0.050 0.058 0.050 0.058
Wang2 0.036 0.042 0.040 0.032 0.036 0.032 0.038 0.038
Chatterjee3 0.044 0.050 0.048 0.040 0.046 0.054 0.048 0.054
Rosner4 0.044 0.052 0.050 0.040 0.052 0.060 0.048 0.056
Does the risk factor effect differ with respect to tumor marker 3 (γ13)?
Polytomous1 0.058 0.042 0.058 0.048 0.046 0.048 0.044 0.042
Wang2 0.044 0.040 0.042 0.038 0.038 0.036 0.032 0.030
Chatterjee3 0.058 0.042 0.056 0.044 0.042 0.048 0.042 0.038
Rosner4 0.058 0.044 0.060 0.048 0.048 0.054 0.046 0.044
Does the risk factor effect differ with respect to tumor marker 4 (γ14)?
Polytomous1 0.058 0.042 0.058 0.048 0.046 0.048 0.044 0.042
Wang2 0.044 0.040 0.042 0.038 0.038 0.036 0.032 0.030
Chatterjee3 0.058 0.042 0.056 0.044 0.042 0.048 0.042 0.038
Rosner4 0.058 0.044 0.060 0.048 0.048 0.054 0.046 0.044
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
CHAPTER 2. COMPARISON OF EXISTING METHODS 38
Table 2.6: Power for different risk factor prevalences q and different alternative hypothesis
scenarios with M = 16 disease subtypes formed by K = 4 individual tumor markers
q 0.3 0.6
Alternative scenario* 1 2 3 1 2 3
Does the risk factor effect differ with respect to subtypes?
Polytomous1 0.332 0.834 0.872 0.260 0.750 0.800
Wang1 0.332 0.834 0.872 0.260 0.750 0.800
Chatterjee1 0.332 0.834 0.872 0.262 0.748 0.798
Rosner1 0.356 0.854 0.880 0.278 0.780 0.816
Does the risk factor effect differ with respect to tumor marker 1 (γ11)?
Polytomous1 0.308 0.596 0.644 0.284 0.538 0.590
Wang2 0.270 0.568 0.638 0.246 0.500 0.558
Chatterjee3 0.296 0.614 0.674 0.274 0.564 0.608
Rosner4 0.308 0.620 0.682 0.280 0.574 0.622
Does the risk factor effect differ with respect to tumor marker 2 (γ12)?
Polytomous1 0.312 0.592 0.646 0.270 0.552 0.602
Wang2 0.280 0.564 0.636 0.232 0.530 0.576
Chatterjee3 0.312 0.614 0.678 0.266 0.564 0.610
Rosner4 0.326 0.630 0.682 0.270 0.574 0.620
Does the risk factor effect differ with respect to tumor marker 3 (γ13)?
Polytomous1 0.298 0.602 0.648 0.300 0.552 0.606
Wang2 0.262 0.562 0.620 0.242 0.502 0.554
Chatterjee3 0.294 0.606 0.654 0.276 0.568 0.606
Rosner4 0.300 0.616 0.666 0.286 0.576 0.618
Does the risk factor effect differ with respect to tumor marker 4 (γ14)?
Polytomous1 0.290 0.610 0.660 0.242 0.540 0.590
Wang2 0.264 0.574 0.634 0.210 0.506 0.560
Chatterjee3 0.288 0.632 0.672 0.238 0.570 0.622
Rosner4 0.296 0.638 0.676 0.250 0.586 0.630
*Alternative scenarios:
1: β1m = {0.2, 0.4, 0.4, 0.4, 0.4, 0.6, 0.6, 0.6, 0.6, 0.6, 0.6, 0.8, 0.8, 0.8, 0.8, 1.0}
2: β1m = {0.2, 0.4, 0.4, 0.4, 0.4, 0.8, 0.8, 0.8, 0.8, 0.8, 0.8, 1.2, 1.2, 1.2, 1.2, 1.2}
3: β1m = {0.2, 0.4, 0.4, 0.4, 0.4, 0.8, 0.8, 0.8, 0.8, 0.8, 0.8, 1.2, 1.2, 1.2, 1.2, 1.4}
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
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the effect was significantly different across disease subtypes according to all subtypes.
2.5 Discussion
This chapter defined two key questions that epidemiologists seek to answer in studies of
etiologic heterogeneity and then showed how to address these questions using each of the
methods that have been proposed. It demonstrated the distinctions of the methods by
creating a unified notation. The simulations show that the stratified logistic regression
method of Rosner et al. (2013) results in substantial biases in parameter estimation for
addressing whether risk factor effects differ across levels of the disease subtype, although it
is acknowledged that this was not a stated goal of the method by the authors. Additionally,
the method is anti-conservative. All other methods have type I error close to the nominal
level. In the simplified setting examined here, whereas the other methods all estimate eight
parameters, the method of Rosner et al. (2013) conditions out the constant terms and only
involves estimation of four parameters. The conditional nature of this model clearly has
implications for the validity of parameter estimates and hypothesis tests related to the
question of heterogeneity across disease subtypes. For addressing whether risk factor effects
differ across levels of each individual tumor marker, polytomous logistic regression and the
two-stage regression with simultaneous estimation method of Chatterjee (2004) perform
similarly with respect to type I error whereas the two-stage meta-regression method of
Wang et al. (2015) is overly conservative and the stratified logistic regression method of
Rosner et al. (2013) is anti-conservative. When differences in type I error are calibrated, all
methods achieve similar power.
In this chapter the focus was on subtypes formed by cross-classification of tumor markers,
and on the distinct influences of the individual tumor markers. In breast cancer research,
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Table 2.7: Full data application to address the question of whether each risk factor differs














Polytomous1 -0.03 0.57 0.16 0.53 <.001
Wang2 -0.03 0.57 0.16 0.53 <.001
Chatterjee3 -0.03 0.57 0.16 0.53 <.001
Rosner4 -0.13 0.52 0.13 0.75 <.001
Age at menarche
(per 2 years)
Polytomous1 0.04 -0.04 -0.00 -0.14 0.065
Wang2 0.04 -0.04 -0.00 -0.14 0.065
Chatterjee3 0.04 -0.04 -0.00 -0.14 0.065
Rosner4 0.06 -0.01 0.04 -0.03 0.041
Nulliparous
Polytomous1 -0.08 0.65 0.21 0.33 0.004
Wang2 -0.08 0.65 0.21 0.33 0.004
Chatterjee3 -0.08 0.65 0.21 0.33 0.004
Rosner4 -0.16 0.59 0.16 0.29 0.002
Age at first birth
(per 5 years)
Polytomous1 0.07 0.01 0.13 0.15 0.343
Wang2 0.07 0.01 0.13 0.15 0.343
Chatterjee3 0.07 0.01 0.13 0.15 0.343
Rosner4 0.02 0.02 0.15 0.14 0.288
Months of
breastfeeding (per 6)
Polytomous1 -0.11 -0.09 -0.22 -0.08 0.566
Wang2 -0.11 -0.09 -0.22 -0.08 0.566
Chatterjee3 -0.11 -0.09 -0.22 -0.08 0.567
Rosner4 -0.09 -0.04 -0.14 -0.09 0.380
Post-menopausal
Polytomous1 -0.23 -0.12 -1.29 -0.75 <.001
Wang2 -0.23 -0.12 -1.29 -0.75 <.001
Chatterjee3 -0.23 -0.12 -1.29 -0.75 <.001
Rosner4 -0.08 0.02 -1.19 -0.64 <.001
Pre-menopausal
BMI (per 20)
Polytomous1 0.34 -0.06 0.98 -0.34 0.010
Wang2 0.34 -0.06 0.98 -0.34 0.010
Chatterjee3 0.34 -0.06 0.98 -0.34 0.010
Rosner4 0.32 -0.20 0.94 0.12 0.005
Post-menopausal
BMI (per 20)
Polytomous1 -0.17 -0.79 -0.19 -0.04 0.490
Wang2 -0.17 -0.79 -0.19 -0.04 0.490
Chatterjee3 -0.17 -0.79 -0.19 -0.04 0.489
Rosner4 -0.14 -0.68 0.09 -0.29 0.456
Oral contraceptive use
Polytomous1 0.07 0.04 -0.25 -0.08 0.497
Wang2 0.07 0.04 -0.25 -0.08 0.497
Chatterjee3 0.07 0.04 -0.25 -0.08 0.497
Rosner4 0.08 0.06 -0.23 -0.08 0.477
Family history of
breast cancer
Polytomous1 0.64 0.88 -0.02 0.73 0.226
Wang2 0.64 0.88 -0.02 0.73 0.226
Chatterjee3 0.64 0.88 -0.02 0.73 0.226
Rosner4 0.42 0.62 -0.29 0.53 0.186
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
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Table 2.8: Full data application to address the question of whether each risk factor differs
across levels of ER and PR status. The model is additionally adjusted for study center.
ER PR
Risk factor Method Estimate p-value Estimate p-value
Age at diagnosis
(per 10 years)
Polytomous1 0.49 <.001 0.07 0.567
Wang2 0.50 <.001 0.06 0.642
Chatterjee3 0.50 <.001 0.06 0.656
Rosner4 0.51 <.001 0.08 0.542
Age at menarche
(per 2 years)
Polytomous1 -0.11 0.225 -0.07 0.439
Wang2 -0.11 0.252 -0.08 0.402
Chatterjee3 -0.11 0.238 -0.08 0.395
Rosner4 -0.11 0.222 -0.08 0.350
Nulliparous
Polytomous1 0.43 0.019 -0.01 0.957
Wang2 0.48 0.009 -0.08 0.648
Chatterjee3 0.49 0.008 -0.09 0.604
Rosner4 0.50 0.006 -0.08 0.653
Age at first birth
(per 5 years)
Polytomous1 -0.01 0.865 0.10 0.206
Wang2 -0.02 0.830 0.11 0.194
Chatterjee3 -0.01 0.910 0.10 0.199
Rosner4 -0.01 0.947 0.11 0.168
Months of
breastfeeding (per 6)
Polytomous1 0.08 0.218 -0.05 0.400
Wang2 0.05 0.367 -0.03 0.648
Chatterjee3 0.06 0.273 -0.03 0.564
Rosner4 0.06 0.267 -0.03 0.558
Post-menopausal
Polytomous1 0.33 0.132 -0.84 <.001
Wang2 0.29 0.185 -0.80 <.001
Chatterjee3 0.30 0.158 -0.81 <.001
Rosner4 0.31 0.147 -0.84 <.001
Pre-menopausal
BMI (per 20)
Polytomous1 -0.86 0.015 0.18 0.602
Wang2 -0.96 0.007 0.29 0.418
Chatterjee3 -1.00 0.006 0.33 0.359
Rosner4 -1.02 0.005 0.31 0.383
Post-menopausal
BMI (per 20)
Polytomous1 -0.24 0.623 0.36 0.445
Wang2 -0.40 0.359 0.55 0.204
Chatterjee3 -0.41 0.311 0.56 0.155
Rosner4 -0.42 0.293 0.59 0.130
Oral contraceptive use
Polytomous1 0.07 0.692 -0.22 0.190
Wang2 0.05 0.785 -0.19 0.241
Chatterjee3 0.04 0.789 -0.19 0.240
Rosner4 0.05 0.778 -0.20 0.227
Family history of
breast cancer
Polytomous1 0.49 0.037 -0.40 0.093
Wang2 0.38 0.082 -0.28 0.198
Chatterjee3 0.38 0.054 -0.28 0.155
Rosner4 0.38 0.051 -0.26 0.173
1Polytomous logistic regression
2Two-stage meta-regression (Wang et al., 2015)
3Two-stage regression with simultaneous estimation (Chatterjee, 2004)
4Stratified logistic regression (Rosner et al., 2013)
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subtypes based on immunohistochemical staining of estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor receptor 2 (HER2) are commonly formed.
Each of these tumor markers can be either positive (+) or negative (-) and the disease sub-
types are defined as luminal A (ER+ or PR+, HER2-), luminal B (ER+ or PR+, HER2+),
HER2-type (ER-, PR-, HER2+), and triple negative (ER-, PR-, HER2-). This configu-
ration is not congruent with the second stage models described in Equations 2.3 and 2.4
on which the methods proposed by Wang et al. (2015), Chatterjee (2004) and Rosner et
al. (2013) are based. Of the methods compared here, only polytomous logistic regression
can address whether a risk factor effect differs across subtypes that are not formed by
cross-classification of the individual tumor markers. This is important for epidemiologic
researchers, who must carefully consider whether the individual tumor markers are of in-
terest, or if it is truly a more complex aggregation of those tumor markers that is expected
to demonstrate a differential association with risk factors.
The methods of Chatterjee (2004) and Rosner et al. (2013) were clearly designed with
the goal of studying multiple tumor markers in a flexible modeling framework. Thus one
can envision a study with a number of tumor markers where the dimension is reduced by
eliminating selected, or all, interactions, and thereby permitting an analysis that would not
be possible in the context of polytomous logistic regression. Further exploration is needed
into the performance of each method under an increasing number of subtypes and risk
factors.
This investigation was limited to methods that require pre-specification of subtypes.
With increasing use of genomic profiling, often it will be of interest to first identify disease
subtypes based on a large number of either binary or continuous tumor markers. Begg et
al. (2013) proposed an approach to address this challenge by introducing a scalar measure
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of heterogeneity that allows an investigator to compare different subtyping configurations
based on, for example, gene expression data. The ultimate investigation of risk factor associ-
ations with the resulting subtypes in this approach relies on polytomous logistic regression.
The scalar measure additionally provides a quantification of the extent of heterogeneity for
a given subtype solution, which the methods discussed in this chapter cannot accommodate.
This approach will be investigated in more detail in the next chapter. Another considera-
tion is the fact that all methods investigated in this chapter use a relative risk structure for
defining and evaluating etiologic heterogeneity. An investigation of how the methods might
be adapted to formulate the issues in the context of additive models is an area of future
work.
In conclusion, the study of etiologic heterogeneity will become increasingly common in
the age of genomic profiling and personalized medicine, and statistical methods are needed
to reliably address these questions. The results of this investigation can serve to guide
selection of a method that will favorably balance statistical and practical considerations.
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Chapter 3
Validity of optimal D clustering?
The results of this chapter show when the strenth of structure in markers that
truly represents etiologic heterogeneity exceeds the strength of structure in tumor
marker data that is unrelated to disease risk, a novel method to cluster tumor
markers and identify disease subtypes that differ maximally works well. However
when this condition is not met, or when there are many tumor markers that simply
represent noise, the truly etiologically heterogeneous subtype solution can still be
identified by first performing variable selection to identify the disease markers most
strongly related to risk factors.
In the previous chapter, a data example and simulation study were used to compare the
statistical properties of methods for investigating etiologic heterogeneity by examining the
differential effects of individual risk factors on pre-defined disease subtypes, or with respect
to individual tumor markers. That study found that when the number of disease subtypes
is small, a simple polytomous logistic regression model performs comparably to the more
complex methods that have since been proposed (Zabor and Begg, 2017). Using polytomous
?Note that the contents of this chapter were submitted for publication in the Annals of Applied Statistics
in July 2018, and are currently under review.
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logistic regression, one can test for differences in relative risks of individual risk factors across
disease subtypes. Polytomous logistic regression relies on there being a small number of
disease subtypes in the context of a case-control study, but it is increasingly common for
epidemiologic studies of cancer to obtain high-dimensional tumor marker information, such
as gene expression, mutation, or copy number data. In such a setting, one must first employ
substantive dimension reduction of the tumor marker data in order to establish a meaningful
framework for examining the effects of the risk factors using a model such as polytomous
logistic regression. To address this problem, earlier work sought to develop a method to
identify the most etiologically distinct subtypes in the context of high dimensional tumor
marker data (Begg et al., 2013). This method involved two critical concepts. First, a scalar
measure that captures the extent of etiologic heterogeneity of any succinct set of mutually
exclusive subtypes was defined. Second, dimension reduction was accomplished through
the use of unsupervised k-means clustering of the tumor marker data. Finally, the scalar
measure of etiologic heterogeneity was calculated for each candidate subtype solution that
resulted from the unsupervised clustering, and the best solution was chosen as the one that
maximized the scalar measure of etiologic heterogeneity. In empirical studies using this
method in breast cancer, melanoma and kidney cancer, the method led to solutions that
were in line with relationships between risk factors and tumor markers that are already well
known to cancer epidemiologists (Begg et al., 2014, 2015; Mauguen et al., 2017).
While these results are encouraging, they do not provide definitive evidence that the
method can accomplish what it sets out to do, which is to identify the subtypes that are
truly the most etiologically heterogeneous. There are reasons to be skeptical. Unsupervised
k-means clustering is designed to identify subtypes that are distinctive with respect to the
Euclidean distances of the markers of cases in a cluster compared to the markers of cases
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in other clusters. But there may exist clusters of cases that are separated on this basis but
which have no relationship with etiology. Such “counterfeit” clusters could confound the
ability of unsupervised clustering to find the clusters of cases that are truly etiologically
distinctive. In this chapter a simulation framework is constructed to address the question
of whether or not the method can be confounded by counterfeit clusters of this nature. The
modeling framework involves creating datasets with the kind of high dimensional structure
that is identifiable by clustering. Structure is created in the data, on the basis of specified
tumor markers, that defines subtypes that are related to the risk factors, and counterfeit
structure is created, on the basis of additional tumor markers, that is unrelated to the risk
factors. Much larger numbers of tumor markers are also generated that neither possess
structure nor are related to risk factors so that they simply introduce noise. The goals
of this chapter are to understand the influences of these two sources of information that
have the potential to prevent the method from identifying the truly etiologically distinct
subtypes. Finally the influence of pre-clustering variable selection is explored as a strategy
for improving the sensitivity of the method.
3.1 Methodologic details
This chapter focuses on a method for the analysis of case-control data, though the approach
could be applied broadly by replacing polytomous logistic regression with an alternative
regression approach appropriate to the study design under consideration. Also, because the
data example comes from breast cancer, the term “tumor marker” will be used throughout,
though all methods could be applied in other disease areas.
The method involves first performing unsupervised clustering of the tumor marker data.
The goal of the unsupervised clustering is to obtain a variety of candidate sets of subtypes
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from which to choose the solution that optimizes the degree of etiologic heterogeneity ob-
served, defined by a measure of etiologic heterogeneity denoted D, which is described in
detail in the next paragraph. K-means clustering with many random starts is used to ob-
tain candidate sets of subtype solutions. K-means clustering seeks clusters that exhibit high
inter-cluster versus intra-cluster Euclidean distance. It is useful for this purpose because
it does not typically reach a global maximum, and therefore when the process is repeated
with different random starts many candidate solutions can be obtained, each at a different
local maximum. In a traditional clustering analysis, one would then select the solution that
maximizes the inter-cluster distance. However, interest is in identifying the class solution
that maximizes etiologic heterogeneity rather than Euclidean distance, and so instead D is
calculated for each of the candidate solutions that result from the different random starts
of k-means clustering, and the solution that maximizes D is chosen as optimal. While al-
ternative clustering algorithms to k-means clustering are not explored in detail, most other
clustering methods are constrained to reach the same solution on every random start and
so would not produce a variety of solutions that could be used to maximize the measure
of etiologic heterogeneity. The fact that k-means clustering produces many potential clus-
tering solutions is the feature that makes it especially useful for this purpose. Section 3.5
includes a cursory exploration of the performance of alternative clustering algorithms in the
context of an analysis of this type.
The methodologic details of the approach have been outlined previously (Begg et al.,
2013). The method involves identifying different clustering solutions, each involving a set of
M disease subtypes, and calculating a measure of etiologic heterogeneity for each solution.
To calculate the measure, denoted D, one must first perform polytomous logistic regression
of the risk factors on the subtypes and obtain estimated risk predictions from this model for
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each of the subtypes for each subject. Since the measure is population-based it is calculated
solely using the study controls. Let i denote these control subjects i = 1, . . . , NH , where
NH denotes the total number of non-diseased control subjects, and let m index the set
of disease subtypes, m = 1, . . . ,M . The risk predictions obtained from the polytomous
logistic regression model for the ith individual are denoted rmi such that the total risk
of disease for that individual is ri =
∑M
m=1 rmi. Let the coefficients of variation of the
subtype risks in the population be denoted C2m = vm/µ
2











i=1 rmi. Let the corresponding total coefficient of variation be denoted
C2 = v/µ2, where µ and v are the overall disease risk mean and variance. Then the measure






m − C2, (3.1)
where pim represents the prevalence of the mth disease subtype. Further details of the ratio-
nale for this measure are provided in Begg et al. (2013). Even though absolute risks cannot
be obtained from a case-control study, the relative risks obtainable from the polytomous
logistic regression model can be used instead since all the terms in D are scale-adjusted.
3.2 Simulation methods
All statistical analyses were conducted using R software (R Core Team, 2018). An R pack-
age containing functions to perform the various calculations included in this analysis is
available on GitHub at https://github.com/zabore/riskclustr. Additional code re-
lated to the specific simulations conducted can be found at https://github.com/zabore/
manuscript-code-repository.
CHAPTER 3. VALIDITY OF OPTIMAL D CLUSTERING 49
3.2.1 Risk factor generation
Individual risk factors are denoted Xp, p = 1, . . . , P , and therefore X = (X1, . . . , XP ). In
order to most clearly highlight the concepts, a simplified setting is used where there are
only P = 2 risk factors, so that X = (X1, X2), and there are M = 3 disease subtypes
that are heterogeneous with respect to the risk factors, as defined below. The density
of the risk factors in the non-diseased, or control, subjects is assumed to follow f(X) ∼
N(0,Σ) and the density of the risk factors in diseased subjects is fm(X) ∼ N(m,Σ), where
m = (m1, m2) represents the mean vector of the two risk factors for disease subtype m.
Equal covariance matrices, Σ, are assumed for diseased and non-diseased subtype risk factor
distributions, since this is congruent with using polytomous logistic regression to model the
conditional probabilities of the disease subtypes given the risk factors (Anderson, 1972). For
convenience in the simulation studies, and without loss of generality, let Σ be the identity
matrix, I, allowing mean values to represent standardized effect sizes. In all simulations 0,
the mean vector for the two risk factors in non-diseased subjects, will be fixed at 0 = (0, 0)
without loss of generality. Then set 1 = (e, 0), 2 = (e/2, e/2), and 3 = (0, e) for the three
disease subtypes. In this way the strength of the differential risk factor associations with
subtypes is represented by a scalar quantity, e.
3.2.2 Tumor marker generation
Risk factor data X are randomly generated from normal distributions with distinct mean
vectors for the controls and for each disease subtype, as described above in Section 3.2.1.
Etiologic heterogeneity is induced in the disease subtypes by generating the tumor marker
data in such a way that certain tumor markers are correlated with the risk factors. Tu-
mor marker data are simulated for case subjects only, and consist of tumor markers that
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are correlated with the risk factors, meaning that these markers possess etiologic het-
erogeneity, as well as tumor markers that are unrelated to the risk factors. Let k in-
dex tumor markers, k = 1, . . . ,K. Tumor markers are denoted T = (TA, TB, TC) where
TA = (T1, . . . , TKA) denotes the set of KA tumor markers related to the risk factors and
(TB, TC) = (TKA+1, . . . , TK) denotes the set of tumor markers that are unrelated to the
risk factors. The tumor markers that are related to the risk factors are distributed as
TA ∼ N(λAm, VAm) where λAm = (λAm1, . . . , λAmKA) represents the mean vector of tumor
markers for subtype m disease, where, as indicated above m = 1, 2, 3. Through the mean
vectors λAm, a relationship between a specific tumor marker and a specific disease subtype
is induced. In this way correlations are also induced between the risk factors X and the
individual tumor markers in TA. The covariance matrix of these markers, VAm, is set to be
the identity matrix, I, for conceptual and interpretive simplicity.
The tumor markers that are unrelated to the risk factors include KB tumor markers
that have the kind of structure that is identifiable by clustering but that are generated
independently of the risk factors. These are denoted TB = (TKA+1, . . . , TKA+KB ). Let
l index the “counterfeit” subtypes defined by the markers in TB, taking the values l =
1, . . . , L. In all included simulation studies let L = 3. Assignment of each case to one of these
L non-etiologically distinct subtypes is randomly generated from a multinomial distribution
with L equal event probabilities, independent of the etiologically distinct class label m. The
tumor markers that characterize these subtypes, TB, are distributed as TB ∼ N(λBl, VBl)
where λBl = (λBl1, . . . , λBlKB ) represents the mean vector of tumor markers for subtype l.
Again, for simplicity, let the variance matrix VBl = I throughout. Through the mean vectors
λBl, a relationship between a specific tumor marker and a specific counterfeit subtype l
is induced, but since these subtypes are assigned to each case randomly, in contrast to
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the subtypes defined by TA for which there is an induced relationship to the etiologically
heterogeneous disease subtypes, there is no relationship induced between the tumor markers
TB and the risk factors X. KC tumor markers, denoted TC = (TKA+KB+1, . . . , TK), that
have no defined structure are also generated . These markers are distributed as TC ∼ N(0, I)
and simply represent noise in the data.
3.2.3 Simulation parameters
For all included simulation studies set N = 2000 subjects, set pi0 = 0.4 to be the sampling
proportion of non-diseased subjects and pim = 0.2, m = 1, 2, 3, to be the sampling propor-
tions of cases in the disease subtypes. Set e = 1.5 so that the mean vectors for the risk
factors are 1 = (1.5, 0), 2 = (0.75, 0.75), and 3 = (0, 1.5) for the three subtypes. Generate
1000 simulated datasets.
The strength of the structure in TA and TB is quantified by the mean vectors λAm
and λBj , respectively, using 15 markers in each group so that KA = KB = 15. Let
λA1 = (a, a, a, a, a, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0), λA2 = (0, 0, 0, 0, 0, a, a, a, a, a, 0, 0, 0, 0, 0), and
λA3 = (0, 0, 0, 0, 0, 0, 0, 0, 0, 0, a, a, a, a, a) be the mean vectors for TA, where a = 1.3 for
weak structure, a = 1.7 for moderate structure, and a = 2.1 for strong structure. These
mean values were selected to achieve separation in clusters, as measured by the inter-cluster
dissimilarity, that is comparable to cluster separation previously seen in real data analyses
(Begg et al., 2014, 2015; Mauguen et al., 2017). Let λB1 = (b, b, b, b, b, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0),
λB2 = (0, 0, 0, 0, 0, b, b, b, b, b, 0, 0, 0, 0, 0), and λB3 = (0, 0, 0, 0, 0, 0, 0, 0, 0, 0, b, b, b, b, b) be the
mean vectors for TB, where b will be varied from 1.275 to 2.3 by small increments, for a con-
tinuum of weaker to stronger structure. In this way the strength of the structure that truly
represents etiologic heterogeneity, and the strength of the unrelated counterfeit structure,
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are characterized by scalars a and b, respectively
3.2.4 Clustering methods
After simulating the tumor marker data, unsupervised k-means clustering with 1000 random
starts is performed on the combined tumor marker data T , or subsets thereof, to obtain a set
of candidate solutions. K-means clustering requires up-front specification of the number
of subtypes of interest, and all included simulation studies specified that 3 subtypes be
identified through clustering. In fact there is the possibility of 9 subtypes, defined by
λAm,m = 1, 2, 3, and λBl, l = 1, 2, 3. However, the goal is to identify the 3 subtypes
defined by λAm that are etiologically heterogeneous. D is calculated based on the predicted
risks from a polytomous logistic regression model that includes all risk factors X using
Equation 3.1 for each of the candidate solutions that result from k-means clustering, and the
clustering solution that maximizes D is identified. To assess the overall ability of k-means
clustering to identify a reliable solution, the number of unique local solutions that occur
among the 1000 random starts of k-means clustering is also recordeed in each simulated
data set. The method relies on being able to determine the optimal solution by selecting
the largest D from a variety of clustering solutions, so accuracy could be compromised in
settings where too few unique cluster solutions are identified.
The misclassification rate is calculated as a measure of how closely aligned the class
solution identified by k-means clustering is to the true class solution. While in a real data
analysis the true class labels would not be known, and therefore it would not be possible
to calculate misclassification rates, in the context of this simulation study misclassification
rates are used to evaluate whether the approach is able to identify the truly etiologically
heterogeneous class solution from which the data are generated. To accomplish this, the
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class labels for the subtype solution that optimizes D are cross-tabulated with the class
labels for the truly etiologically heterogeneous subtype solution. Then the misclassification
rate is calculated as 1 −∑ d/NU , where d indicates the diagonal of the cross-tabulation
and NU indicates the total number of cases. Since the labels that result from clustering are
arbitrary, the class labels for the optimal solution must first be aligned with the true class
labels by identifying the configuration that minimizes misclassification as defined above. An
alternative measure for misclassification that is sometimes used would involve identifying
whether a pair of cases who are classified similarly according to the truly etiologically
distinct subtype solution are also classified similarly according to the subtype solution that
optimizes D. The proportion of pairs of cases classified differently to the total number of
pairs of cases would represent the misclassification. In a single simulation scenario, these
two measures of misclassification were found to be highly comparable, with the measure
based on pairs of cases consistently resulting in slightly lower levels of misclassification as
compared to the measure based on each case’s individual class membership, indicating that
this alternative measure would not lead to meaningful differences in the pattern of results.
The influence of pre-clustering variable selection is then explored. To this end KC =
70 additional tumor markers TC that have no structure and are not related to the risk
factors are included as a way to add noise to all simulation settings that were previously
described, resulting in a total of 100 tumor markers. To achieve dimension reduction, the
tumor markers are first ranked according to the D values that characterize the individual
contributions of each marker to etiologic heterogeneity. These are obtained by creating
two classes defined by high versus low values of each marker classified at the median,
and using polytomous logistic regression and Equation 3.1 to obtain D. In this way an
ordering of the tumor markers from most heterogeneous with respect to the risk factors to
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least heterogeneous with respect to the risk factors can be obtained. The analysis is then
restricted to the markers with higher heterogeneity by sequentially reducing the ordered
tumor marker set from K = 100 through K = 5 by increments of 5. The continuous
versions of all selected tumor markers are then used in the clustering and the optimal D is
identified, for each number of selected markers. This allows for exploration of the extent of
misclassification as a function of the degree of dimension reduction.
Finally the influence of including an increasingly large set of tumor markers TC that
have no structure and are not related to the risk factors is examined. To simplify the
interpretation, the KB markers with counterfeit structure are eliminated. Set a = 1.7,
representing moderate strength of structure in the KA tumor markers that are related to
the risk factors. Then increase the number of unstructured tumor markers that are included
from TC = 50 to TC = 15000 to see how many such noisy tumor markers must be present
in the data before the approach can no longer reliably identify the true class solution.
There are some additional considerations when using k-means clustering to obtain can-
didate sets of subtype solutions. It is sometimes possible for k-means clustering to result in
a local maximum that has low inter-cluster dissimilarity. These scenarios were arbitrarily
avoided by selecting the optimal class solution as the one that has maximal D from the
subset of class solutions with sufficiently high dissimilarity, defined as a dissimilarity at least
greater than the average dissimilarity across all k-means solutions. Additionally, on rare
occasions k-means clustering will result in a solution with one or more very small classes. A
class solution of this type would not be suitable for use in a polytomous logistic regression
model, therefore calculation of D was restricted to solutions where each class consisted of
at least 20 cases.
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3.3 Results
The primary measure of success is the accuracy by which the data are classified into the
three truly etiologically distinct clusters m = 1, 2, 3. This success is represented by a low
misclassification rate. Also, when the prevalence of each subtype in the source population
is known, with known risk factor distributions, the true population value of D can be
established. Given the mean vectors for the risk factors are 1 = (1.5, 0), 2 = (0.75, 0.75),
and 3 = (0, 1.5) for each of three subtypes, and the prevalence of each of the three subtypes
in the population is 0.2, the true population value of D is 0.506. The simulations seek to
evaluate whether the method can achieve estimates of D that approach this true population
value.
3.3.1 Impact of counterfeit structure
First, the influence of including tumor markers with counterfeit structure, unrelated to the
risk factors, is addressed. Here the analysis is restricted to (TA, TB), the KA = 15 tumor
markers that have structure related to the risk factors and the KB = 15 tumor markers that
have structure unrelated to the risk factors, for a total of 30 tumor markers. On average
across the various simulation settings, k-means clustering results in a variety of unique
clustering solutions. The average number of unique solutions across all simulation settings
is approximately 20 unique solutions from the 1000 random starts of k-means clustering,
with a minimum number of 12, when a = 1.7 and b = 1.275, and a maximum of 48, when
a = 1.3 and b = 1.275. Recall that a variety of solutions is needed in order for the method
to produce candidate solutions with a range of etiologic heterogeneity, since identification
of the various clustering solutions is not influenced directly by the risk factors.
The average misclassification rates are shown in Figure 3.1A. Note that the scale of the
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Figure 3.1: Average minimum misclassification (A) and average maximum D (B) across
varying strengths of structure in the tumor marker data based on KA = 15 tumor markers
with structure related to the risk factors and KB = 15 tumor markers with structure
unrelated to the risk factors. a = strength of structure in tumor markers related to risk
factors, b = strength of structure in tumor markers unrelated to risk factors. A darker color
indicates a higher value.
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axis according to b is not evenly spaced but rather contains informative values. Darker colors
denote higher values, which are undesirable since minimization of the misclassification rate
is sought. As the strength of structure in the tumor markers that are unrelated to the risk
factors, denoted by b, increases, the estimated misclassification rates increase. The smallest
estimated misclassification rate of 0.001 occurs when a = 2.1, that is, when the structure in
the tumor markers that are related to the risk factors is strong. This value indicates that
on average only 1 case is being misclassified in this setting. When the strength of structure
in the tumor markers that are related to the risk factors is weak and moderate, minimum
misclassification rates of 0.039 and 0.007, respectively, are achieved. As b equals and then
surpasses a, the misclassification rates increase rapidly. For example when a = 2.1 and
b = 2.3 the misclassification rate is 0.647, which means that the chance of a misclassification
is essentially random since there are three subtypes of which only one is the correct subtype.
Clearly the method is preferentially selecting the counterfeit subtypes that are defined by
the markers in TB.
The average maximum values of D are shown in Figure 3.1B. Darker colors denote higher
values, which are desirable since maximization of D is sought. As b increases, estimates of
D decrease. The largest estimated D of 0.561 occurs when a = 2.1, where the structure
in the tumor markers that are related to the risk factors is strong. This value exceeds the
true population value of D of 0.506. This overoptimism is presumably due to the effect of
picking the largest value of D in a setting where these are estimated and thus subject to
statistical variation. Also, when a = 2.1 the estimated D drops quickly as b approaches and
then exceeds a, similar to the trends seen in Figure 3.1A. When the strength of structure in
the tumor markers that are related to the risk factors is weak and moderate, maximum D
estimates of 0.479 and 0.547, respectively, are achieved and similar patterns to those seen
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for the misclassification rates are seen with respect to the rapid drop in estimated D as the
strength of structure in the tumor markers that are unrelated to the risk factors equals and
then surpasses the strength of structure in the tumor markers that are related to the risk
factors. Overall these results indicate that the clustering will identify with high probability
the class solution with the strongest signal, regardless of whether the solution represents
clusters that are related to risk factors or not.
3.3.2 Pre-clustering variable selection
To try to improve these properties, the influence of pre-clustering variable selection is ad-
dressed. In these simulations KC = 70 tumor markers in TC that have no structure and are
not related to the risk factors are included in addition to the tumor markers with structure
in TA and TB, for a total of 100 tumor markers. The first observation is that when the full
data T = (TA, TB, TC) are included in k-means clustering, there is no substantial impact
on the results described in Section 3.3.1 (Figure 3.2). Next it is examined whether variable
selection of tumor markers prior to clustering, based on their individual relationships with
the risk factors as measured by their individual values of D, can improve the properties of
the method. After rank-ordering the individual tumor markers based on their individual
contributions to heterogeneity and reducing the set sequentially from 100 to 5 by increments
of 5 tumor markers, the resulting misclassification rates are found to be uniformly low when
a relatively small number of tumor markers are included, since most of the included tumor
markers in this setting are selected to have structure related to the risk factors (Figure 3.3).
Additionally, when the strength of structure in the tumor markers in the counterfeit clus-
ters (represented by b) is less than the strength of structure in the tumor markers that
are related to the risk factors (represented by a), all 100 tumor markers can be included
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Figure 3.2: Average minimum misclassification (A) and average maximum D (B) across
varying strengths of structure in the tumor marker data based on KA = 15 tumor markers
with structure related to the risk factors and KB = 15 tumor markers with structure
unrelated to the risk factors and KC = 70 tumor markers that represent noise. a = strength
of structure in tumor markers related to risk factors, b = strength of structure in tumor
markers unrelated to risk factors. A darker color indicates a higher value.
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Figure 3.3: Average minimum misclassification for varying strengths of structure in the
tumor markers with structure unrelated to the risk factors (denoted b), across different
numbers of tumor markers included in k-means clustering based on univariate D ranking,
according to the strength of structure in the tumor markers with structure related to the
risk factors (denoted a). The color represents the difference in strength for the two types
of markers, b− a.
with little to no impact on the results (green lines in Figure 3.3). When the strength of
structure in the tumor markers in the counterfeit clusters is approximately equal to the
strength of structure in the tumor markers that are related to the risk factors, reasonable
misclassification rates can be achieved by reducing the dimension of the tumor marker set
by about half (yellow lines in Figure 3.3). However, when the strength of structure in the
tumor markers in the counterfeit clusters surpasses the strength of structure in the tumor
markers that are related to the risk factors, much more stringent dimension reduction is
required before reasonable misclassification rates can be achieved (red lines in Figure 3.3).
Since neither noisy markers in TC nor the undesirable structured markers in TB are
related to disease risk, these markers compete with each other on an equal footing in the
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variable selection strategy, while the markers related to the risk factors in TA are selected
preferentially, as desired. This suggests a somewhat paradoxical result, that a larger number
of noisy markers is beneficial by making it increasingly difficult for the confounding markers
to be selected, provided that the variable selection is sufficiently strict (Figure 3.4). However,
logic suggests that if there are too many noisy markers it will be increasingly difficult for
the structure defined by markers with the true signal to be identified. To examine this,
the number of noisy tumor markers, TC , is increased incrementally from 50 to 15000 to see
when the truly etiologically heterogeneous structure defined by the 15 markers in TA can no
longer be successfully identified. As the number of unstructured tumor markers increases,
average minimum misclassification increases, with large changes in misclassification between
1500 and 5000 tumor markers (Figure 3.5). The impact of additional tumor markers is more
pronounced at the smaller numbers when the strength of structure in the tumor markers
related to the risk factors is weak.
3.4 Data application
The goal in the data application is to cluster gene expression data to identify breast cancer
subtypes that demonstrate the highest degree of etiologic heterogeneity. Data from the
Cancer and Steroid Hormone (CASH) breast cancer case-control study are analyzed. This
study includes data from 2990 population controls and 551 breast cancer cases with a panel
of gene expression data related to estrogen receptor status, 202 genes in total. The data also
include standard breast cancer risk factors. In line with previous research (Gaudet et al.,
2011) age at diagnosis, race, premenopausal body mass index (BMI), postmenopausal BMI,
family history of breast cancer, prior benign breast disease, age at menarche, nulliparity,
number of live births (parity), age at first birth, months of breastfeeding, and menopausal
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Figure 3.4: Number of each type of tumor marker (TA, TB, TC) selected as the size of the
selected tumor marker set increases, averaged across all simulation settings.
Figure 3.5: Average minimum misclassification as the number of unstructured tumor mark-
ers KC increases, according to the strength of structure, a, in tumor markers related to risk
factors.
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status are included as risk factors, and estimates are additionally adjusted for study center.
Results based on individual gene expression values were reported in Begg et al. (2015).
As in the simulation studies, k-means clustering on the full set of gene expression data
is performed using 1000 random starts. Then D is calculated for each candidate solution
based on a polytomous logistic regression model incorporating all risk factors and using
Equation 3.1, and the optimal solution is identified as the one with maximal D. Next, to
examine pre-clustering variable selection, D is calculated for each tumor marker individually
to test for etiologic heterogeneity based on the gene expression values dichotomized at the
median, using 500 permutations of the data, and these p-values are adjusted for multiple
comparisons using the false discovery rate method. A reduced gene set is selected for k-
means clustering based on the genes that have an adjusted p-value < 0.05. This method
differs from that used in the simulation study because in a real data analysis interest is in
selecting only genes that are believed to carry a meaningful heterogeneity signal whereas in
the simulations the effect of including different numbers of noisy markers was being studied.
Because there is a well-established set of four breast cancer molecular subtypes, based on
immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PR) and
human epidermal growth factor receptor 2 (HER2), clustering is focused on M = 4 classes.
Clustering the full set of 202 genes, a value of D = 0.198 is obtained. Limiting the gene
set to those genes with a permutation-based p-value < 0.05 after adjustment for multiple
comparisons results in a reduced set of 33 genes. Clustering the reduced gene set leads
to a considerably higher optimal D of 0.331. In line with the simulation results, excluding
tumor markers that are not associated with etiologic heterogeneity prior to clustering allows
for identification of a more strongly heterogeneous solution. In a real application of this
nature misclassification rates cannot be evaluated since the true subtypes are unknown.
CHAPTER 3. VALIDITY OF OPTIMAL D CLUSTERING 64
However, the alignment of the class solutions can be examined with the established set
of four breast cancer molecular subtypes: luminal A (ER+ or PR+, HER2-), luminal B
(ER+ or PR+, HER2+), HER2-type (ER-, PR-, HER2+), and triple negative (ER-, PR-
, HER2-) (Table 3.1). While there are differences between the class solutions based on
the optimal D approach and the standard IHC-based molecular subtypes, there is more
alignment of results after performing up front selection of gene expression values to include
in the clustering, with the alignment increasing from 47% to 50%. Interestingly, the D
estimate for the standard set of subtypes is 0.268, considerably lower than the optimal
classification.
Table 3.1: Cross-tabulation of optimal D clustering results on full and reduced gene sets
according to a well-established set of four subtypes in the CASH data.
Standard molecular subtypes
Optimal class solutions HER2-type Luminal A Luminal B Triple negative
Full gene set
1 23 102 15 34
2 24 134 17 12
3 1 19 2 7
4 18 17 11 82
Reduced gene set
1 46 60 27 27
2 8 118 12 13
3 1 89 6 4
4 11 5 0 91
3.5 Additional clustering algorithms
In the primary results, the use of a novel clustering strategy that involved performing
k-means clustering with 1000 random starts, calculating D for each resulting candidate
class solution, and then selecting the solution that results in maximal D as the optimal
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clustering solution was proposed. However, there are alternative clustering algorithms
available. The original results based on this novel clustering strategy, referred to here
as optimal D (“optD”), are compared with results produced from standard k-means clus-
tering (“Kmeans”), partitioning around medioids (“PAM”), and model-based expectation-
maximization (EM) clustering (“Mclust”).
K-means clustering, when used in its standard form, selects the clustering solution
that minimizes the ratio of the within-cluster sum of squares to the between-cluster sum
of squares based on squared Euclidean distance (MacQueen, 1967). PAM is similar to
k-means clustering, except it minimizes a sum of dissimilarities rather than the sum of
squared Euclidean distances (Kaufman and Rousseeuw, 1987). Finally, model-based EM
clustering (Fraley and Raftery, 2002) relies on Gaussian mixture modeling fitted via the EM
algorithm. This approach fits numerous models and then selects the best model according
to the Bayesian information criterion (BIC).
In all simulation settings there are P = 2 risk factors with the same mean vectors as
described in the primary results. The sample size is N = 2000 and 1000 simulated datasets
are generated. The proportion of controls is pi0 = 0.4. When k-means clustering is used, it is
used with 1000 random starts. Up-front variable selection is performed as described in the
primary methods. In all settings there are KA = 15 tumor markers with structure related
to the risk factors, which comprise M = 3 etiologically distinct subtypes with moderate
strength of structure defined by a = 1.7.
This section seeks to accomplish two things:
1. To compare optimal D clustering to other clustering methods when there is structure
related to the risk factors in addition to counterfeit structure
CHAPTER 3. VALIDITY OF OPTIMAL D CLUSTERING 66
Figure 3.6: Misclassification rate according to strength of counterfeit structure, comparing
clustering methods.
2. To evaluate optimal D clustering in comparison to other clustering methods when
assumptions including constant variance, balanced class sizes, and normality do not
hold
3.5.1 Clustering comparison in the presence of counterfeit structure
First, optimal D clustering is compared to other clustering methods when there is structure
related to the risk factors in addition to counterfeit structure. To accomplish this, the perfor-
mance of the different clustering algorithms is compared in the presence of KB = 15 tumor
markers with counterfeit structure that comprise L = 3 classes. Let b = 1.75, 1.775, or 1.8
to explore several strengths of counterfeit structure. There are equal proportions of cases
pi1 = pi2 = pi3 = 0.2 in each class related to the risk factors.
To assess the ability of the different clustering methods to identify the truly etiologically
heterogeneous subtype solution as the strength of counterfeit structure varies, misclassifi-
cation rates are examined. Figure 3.6 shows that optimal D clustering always performs at
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least as well as the other clustering algorithms in this setting, and when 30 or 25 of the 30
tumor markers are included in the clustering, optimal D clustering outperforms the other
approaches (orange line). When dimension reduction to 20 or 15 of the tumor markers is
performed, k-means clustering and model-based EM clustering perform approximately as
well as optimal D clustering. PAM does not perform as well as the other approaches even
with dimension reduction.
3.5.2 Clustering comparison under assumption violations
Next, optimal D clustering is evaluated in comparison to other clustering methods when
assumptions do not hold. In the following sections counterfeit structure is not included, but
rather the performance of the clustering methods under different assumption violations in
the presence of KC = 15 unstructured tumor markers is compared.
3.5.2.1 Heteroskedastic data
Because it is widely believed that k-means clustering does not perform as well when data are
heteroskedastic, the influence of unequal variance in the tumor markers that comprise the
different classes is examined. To accomplish this, in two of the three classes, the variance
of the five tumor markers related to each class is fixed at VA1 = VA2 = 1 as in the primary
results. However for the third class, the variance of the five tumor markers that comprise
this class is varied from VA3 = 1.5 to VA3 = 2 to VA3 = 2.5 to explore the impact of
increasing the variance for the tumor markers in only one of the three classes.
Figure 3.7 shows that optimal D clustering, k-means clustering, and model-based EM
clustering have similar misclassification rates across all numbers of included tumor markers,
though model-based clustering performs slightly better when the variance of the third class is
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Figure 3.7: Misclassification rate according to variance of the third class, VA3, comparing
clustering methods.
VA3 = 2.5 (note that the y-axis is on the log scale). PAM always has higher misclassification.
3.5.2.2 Unbalanced class size
Next the impact of unbalanced class sizes is examined. To accomplish this the proportions
of cases in each class are varied such that two of the three classes have equal size and the
third contains a larger proportion of cases. In the first setting pi1 = pi2 = 0.15 and pi3 = 0.3,
in the second setting pi1 = pi2 = 0.125 and pi3 = 0.35, and in the third setting pi1 = pi2 = 0.1
and pi3 = 0.4.
Figure 3.8 shows that optimal D clustering, k-means clustering, and model-based EM
clustering have similar misclassification rates, with model-based clustering having slightly
lower misclassification when the third class contains pi3 = 0.4 of the cases. PAM has
uniformly higher misclassification.
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Figure 3.8: Misclassification rate according to proportion of cases in the third class, pi3,
comparing clustering methods.
3.5.2.3 Non-normal tumor marker distributions
Because k-means clustering relies on Euclidean distance it is commonly understood that it
is optimized for normally distributed data, which has been used in all results in the primary
analyses. To examine this, the different clustering methods are compared under a variety
of data distributions. Specifically, data from a log-normal distribution with mean 0 and
standard deviation 0.5, binary data based on a dichotomization at the median of normally
distributed tumor markers with mean 0 and standard deviation 1, and binary data based
on a dichotomization at the median of log-normally distributed tumor markers with mean
0 and standard deviation 0.5 are clustered.
Figure 3.9 shows that in most cases, optimal D clustering, k-means clustering, and
model-based EM clustering result in very similar misclassification rates. PAM results in
uniformly higher misclassification rates.
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Figure 3.9: Misclassification rate according to different data distributions, comparing clus-
tering methods.
3.5.3 Clustering comparison conclusions
Overall, because optimal D clustering results in a variety of class solutions from which
the solution that maximizes D, a measure of etiologic heterogeneity, is selected, in some
circumstances this method is able to identify a class solution with lower misclassification
as compared to other clustering methods. Additionally, though the optimal D clustering
approach relies on k-means clustering, which in recent years has been utilized less than
more modern clustering techniques such as model-based EM clustering, this analysis found
that k-means clustering is not impacted by assumption violations more strongly than any
of the other clustering methods examined here. Therefore, the novel clustering approach,
optimal D clustering, which is based on k-means clustering, can reliably be used across a
variety of data types and is able to identify the truly etiologically heterogeneous subtype
solution in the presence of counterfeit structure more often than other clustering methods.
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3.6 Discussion
In this chapter the performance of the optimal D clustering method was examined with
respect to its ability to identify etiologically heterogeneous subtypes. When the structure
in the tumor markers defining etiologic heterogeneity is strong, these etiologically distinct
subtypes can be identified successfully with low misclassification even in the presence of
weaker “counterfeit” structure. As the strength of the true structure decreases, misclas-
sification rates increase. When the strength of the counterfeit structure surpasses that of
the true structure, the desired etiologically heterogeneous subtypes can no longer be identi-
fied without variable selection to reduce dimension purposefully. Misclassification rates are
not substantially impacted by the inclusion of a relatively small number of unstructured
tumor markers, but this impact increases as the number of unstructured tumor markers
becomes large. Since the ability of the method to identify the truly most etiologically dis-
tinct subtypes is impacted by both inclusion of tumor markers with strong structure that
are unrelated to the risk factors and inclusion of a large number of unstructured tumor
markers, a method to filter out such tumor markers will play an important role in any anal-
ysis of this type. Initial selection of tumor markers on the basis of their association with
the risk factors led to improved performance across all simulation settings, and in the data
application. This suggests that with careful use of up-front selection of tumor markers, the
clustering method can reliably identify the truly etiologically distinct subtypes from high
dimensional tumor marker data, although clearly the accuracy of the method will depend
on the strength of the signal in the etiologic heterogeneity that distinguishes the subtypes.
However, there is no obvious strategy for determining where to draw the line in selecting
tumor markers for inclusion, and so in practice analyses of this type will require judgment.
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Because of the inherent complexity of unsupervised clustering in high-dimensional data
of this type, these simulation studies were conducted in a highly simplified context. In real-
ity, genomic tumor marker data frequently have a much higher dimension and will possess
much more complex structure than represented by this idealized framework. However, it is
difficult to simulate complex structures meaningfully. The intent in this investigation has
been to create a framework to permit one to infer generalizable messages that are relevant
to the data analytic strategy.
An important area of future work will focus on how to estimate the optimal number of
subtypes in a clustering analysis of this type. Estimation of the correct number of clusters
is a challenge in any unsupervised clustering analysis, no matter the goal. One popular
method is to use the gap statistic, which compares the within-cluster sum of squares to
that expected under a null reference distribution for the data (Tibshirani et al., 2002). In
the included simulation studies the true number of etiologically distinct disease subtypes
was fixed at three and a search for three clusters was specified in the k-means algorithm.
However in a real data analysis the true number of subtypes will not be known. Future work
is needed to create an appropriate method for estimating the optimal number of subtypes.
In summary, this chapter supports the following conclusion about the use of this cluster-
ing method for identifying etiologically heterogeneous subtypes. The method is capable of
finding the true subtypes if they exist. However, the accuracy will depend on the strength
of the heterogeneity signal, and the method is greatly enhanced with minimal cost by using
pre-clustering variable selection of the tumor markers that are observed to be most strongly
associated with the risk factors.
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Chapter 4
Application to Carolina Breast
Cancer Study
The results of this chapter show that by using a novel method to cluster gene
expression data and identify disease subtypes that differ maximally with respect
to etiologic heterogeneity using data from the Carolina Breast Cancer Study, an
etiologically distinct 4-subtype solution was identified in a discovery stage, and in a
validation sample showed reasonable validation in terms of both the highest-ranked
individual genes and the subtypes formed by selected genes. PSPHL was the most
important gene in defining etiologically distinct subtypes, and age, postmenopausal
body mass index, ever use of oral contraceptives, and race are the risk factors that
demonstrate etiologic differences across the optimal subtype solution.
As described in the Introduction (Section 1.3), there are four well-defined subtypes of breast
cancer, known as luminal A, luminal B, HER2-type, and basal-like/triple negative. These
subtypes have been used in numerous epidemiologic studies of etiologic heterogeneity, but
they were originally discovered with the goal of separating patients according to prognosis,
not risk. In previous work an approach that combines a search for candidate subtypes of
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cancer based on genomic information with use of a scalar measure to identify the most
etiologically heterogeneous subtype solution was proposed (Begg et al., 2013), and the
previous chapter established that with rigorous up front selection of the tumor marker
data the method identifies the true subtype solution with high probability. This chapter
seeks to apply this approach to data from a large population-based breast cancer case-
control study with available gene expression data to determine the optimally heterogeneous
subtype solution with respect to risk for disease. Defining etiologically distinct subtypes of
disease based on known risk factors will yield improved power to identify new risk factors,
especially germline risk factors, that are expected to demonstrate etiologic heterogeneity
and therefore will have increased effect sizes associated with certain subtypes of disease,
thus leading to smaller and more efficient studies.
4.1 Carolina Breast Cancer Study data
The Carolina Breast Cancer Study (CBCS) was conducted in three phases from 1993
through 2013. The details of the study methodology, including sampling stratification
and sampling frequencies, have been previously described in detail (Furberg et al., 2002,
2003; Newman et al., 1995). Briefly, women aged 20-74 living in certain counties in North
Carolina and diagnosed with a first primary breast cancer were identified from the North
Carolina Central Cancer Registry. Black women and women < 50 years old were over-
sampled with specific sampling probabilities. Controls were frequency matched to cases by
race and 5-year age group. Phase 2 of the study included cases of DCIS, but the following
analyses are limited to invasive breast cancer cases. Additionally, the analyses are limited
to cases with available data on a panel of gene expression values. The analysis includes
available, known risk factors for breast cancer.
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Phases 1 and 2 had case-control designs whereas phase 3 was a case-only study design
and thus did not include a sample of matched control subjects. There were a total of 861
cases and 790 controls in phase 1, 947 cases and 774 controls in phase 2, and 2976 cases in
phase 3. Because an analysis of this type is already quite complex, methods to account for
missing data such as multiple imputation are not feasible to implement, so a complete case
analysis was conducted. See Figure 4.1 for details of patient exclusions.
4.1.1 Gene expression processing
The gene expression data in this study were obtained using a custom NanoString codeset
for 406 genes of interest. See Section 4.5 for a full list of genes included in this analysis. Per-
formance of the nCounter assay was assessed for efficiency and sub-optimal hybridization.
Expression levels below the mean of negative controls were set to the mean background
expression. Then positive control normalization multiplied all counts for a sample by the
ratio of the average geometric mean of positive controls across all samples to the geometric
mean of the sample-specific positive controls. Reference gene normalization was done in
a similar way based on a set of 11 housekeeping genes. Batch effects were corrected by
calibrating each lot based on a scaling factor calculated as the average geometric mean of
endogenous genes across the three lots to the geometric mean of endogenous genes within
lot. Finally, expression counts were log2 transformed.
Visualizations using 1-way dendograms and principal components analysis were used
to identify major outliers. A sample was considered a major outlier if, after all of the
pre-processing described in the previous paragraph was complete, the sample demonstrated
extreme expression across all genes. During the quality control process 126 samples were
flagged and excluded from analysis as major outliers according to principal components
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analysis (Figure 4.1). In a sensitivity analysis clustering a set of cases that included the
major outliers, when compared to the results from the primary analysis with the major
outliers excluded, between 94% and 99% of cases were classified similarly, suggesting that
these major outliers did not comprise a separate etiologically distinct class. Gene expression
values were standardized within sample by subtracting the mean gene expression for that
sample and dividing by the sample standard deviation. Finally each gene’s expression
was median centered. Twenty cases from phases 1 and 2 and 20 cases from phase 3 were
randomly selected for removal from the case group to test for differences between the various
phases of the study, which were conducted at different times, without compromising the
overall type I error of the primary results. The overall gene expression distributions between
the different phases were compared using histograms and a Wilcoxon rank-sum test.
The final sample sizes for analysis are 83 cases and 739 controls from phase 1, 287 cases
and 716 controls from phase 2, and 467 cases from phase 3 (Figure 4.1).
4.2 Methods
The analysis is conducted in two stages:
1. Cluster discovery stage. The 467 phase 3 cases with available gene expression and risk
factor data are used to determine the optimally etiologically heterogeneous clustering
solution using a case-only analytic setting.
2. Cluster validation stage. The 370 cases with available gene expression and risk factor
data and the 1455 controls with available risk factor data from phases 1 and 2 are
pooled, and the cases are assigned to a class solution based on the discovery results.
Polytomous logistic regression is performed in the case-control setting to identify risk
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factors with heterogeneous effects.
The goal of conducting the analysis in two stages, with discovery followed by independent
validation, is to ultimately be able to obtain valid odds ratio estimates and p-values testing
for heterogeneity across the subtypes. If the subtypes were discovered using the same data
in which testing for heterogeneity was then conducted, the resulting p-values would be
over-optimistic, since the risk factor distributions are pivotal in selection of the optimal
subtype solution. The data were split into discovery and validation stages based on the
original CBCS study design, which in phase 3 collected data only on cases with no matched
controls, and in phases 1 and 2 collected data on cases with frequency matched controls.
This approach of using the phase 3 data for discovery and the phases 1 and 2 data for
validation is consistent with the original design of the study, which collected these data
in different years and with different study designs. Use of the phases 1 and 2 data for
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validation additionally allows for calculation of standard case-control odds ratios.
4.2.1 Clustering methods
In the cluster discovery stage, a novel clustering method that uses unsupervised k-means
clustering of the gene expression data in combination with calculation of a scalar measure of
etiologic heterogeneity based on all available risk factors is applied to identify the optimally
etiologically heterogeneous subtype solution, as detailed in Section 3.1 of Chapter 3. In
the setting of a case-control study, the scalar measure of etiologic heterogeneity, denoted
D, is calculated according to Equation 3.1. An approximation of this measure, denoted
D∗, can be applied in the case-only setting, and details of this approach can be found in
Begg et al. (2013). Briefly, whereas the variance and covariance terms in Equation 3.1 are
averaged over the controls in a case-control setting, in a case-only setting they are averaged
over the cases, which represent a risk-biased sample from the population. The goal of an
analysis of this type is not to interpret the magnitude of D, but rather to use D to rank
different subtyping schemes and identify the one that maximizes etiologic heterogeneity,
and rankings based on D and D∗ are expected to be broadly similar in practice.
K-means clustering is performed with 1000 random starts on the gene expression data
in the discovery cases, to obtain a variety of class solutions. For each candidate solution
identified by k-means clustering, D∗ is calculated and the solution that maximizes D∗ is
selected as the optimal solution. To avoid solutions with subtypes with very small sample
sizes, clustering solutions where a class had fewer than 20 cases were not considered. Ad-
ditionally, because the true number of subtypes is unknown, the optimal 2-class, 3-class,
4-class, and 5-class solutions were identified and the ideal number of classes was later se-
lected from these options. Solutions with more than 5 classes were not considered due to
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sample size limitations and in order to avoid overfitting.
4.2.2 Gene selection
The simulation studies presented in Chapter 3 found that when there exists strong multi-
variate structure in the tumor marker data that is unrelated to the risk factors of interest,
or when there are many tumor markers that simply represent noise, the optimal D clus-
tering method can fail to identify the subtype solution that is truly the most etiologically
heterogeneous. However, this problem was relatively easily overcome by performing up-
front variable selection on the tumor marker data. To accomplish the selection of genes,
the individual D∗ value for a 2-class solution is calculated for each gene. The 2-class solu-
tion for each gene is identified using standard k-means clustering optimized by inter-cluster
distance and searching for two classes in the entire case sample (i.e. all phase 1, 2, and 3
cases combined). The genes are then rank-ordered according to their individual D∗ values
from the most heterogeneous to the least heterogeneous gene.
Because some genes in the included NanoString codeset are known to be highly corre-
lated, an adjustment to the ranking based on correlation is considered. First, the top-ranked
gene was used as the predictor in a linear model and each remaining gene was used as the
outcome. The R2 value was obtained from each linear model, where a larger R2 represents
a situation where the top-ranked gene better predicts the value of the gene under consider-
ation in the outcome of the model. Each gene’s individual D∗ value was then weighted by
the inverse of the resulting R2 so that genes strongly related to the top-ranked gene would
be down-weighted and genes weakly related to the top-ranked gene would be up-weighted.
The remaining genes were then re-ranked. Next, the top two genes were used as predictors
in a linear model and each remaining gene was used as the outcome. The R2 values were
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obtained and used to weight the individual D∗ values and adjust the ranking accordingly.
This process was repeated until the top 10% of genes, or 40 genes, was obtained for inclusion
in the reduced gene set. Solutions with fewer than 40 genes were investigated subsequently,
as described in Section 4.2.6.
4.2.3 Validation
In the validation stage, each validation case (i.e. cases from CBCS phases 1 and 2) is
assigned to the discovery class solution to which it is most similar. To accomplish this,
the cluster centroids are first calculated in the discovery cases by averaging the data points
within each of the M subtypes. Next, the Euclidean distance between each validation
case and each of the M discovery cluster centroids is calculated. Each validation case is
assigned to the closest cluster, defined as the one that demonstrates minimum Euclidean
distance. D is calculated for each resulting subtype solution for comparison with the extent
of heterogeneity as quantified by the traditional IHC and the traditional PAM50 subtype
solutions.
To validate the subtypes identified in the discovery stage, the process of ranking the genes
to obtain a reduced set and identifying the optimal solutions of different sizes is repeated
in the phases 1 and 2 data, to obtain a validation solution. Both selection of the included
genes and clustering of the reduced gene set to identify the optimal solution are conducted
independently in the discovery and validation data. The optimal discovery class solution
and the optimal validation class solution are then cross-tabulated, with validation cases
assigned to discovery cluters as described above, to examine the alignment of validation
cases according to the two independent classifications, as a way to assess the replicability
of the identified subtypes.
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The rest of the analyses are conducted in the validation data using the subtypes defined
by the discovery class solution. Univariable associations between risk factors of interest
and the resulting subtypes are examined using the Wilcoxon rank-sum test for continuous
variables and the Chi-squared test for categorical variables. Then a polytomous logistic
regression model is fit for the subtypes versus controls using all risk factors of interest, and
adjusting for study phase 1 versus 2. For each risk factor p, p = 1, . . . , P , the regression
parameters βˆpm are obtained from the polytomous logistic regression model (Equation 2.1).
These regression parameters are exponentiated to obtain odds ratios exp (βˆpm) as a measure
of effect size. Finally, a heterogeneity p-value is calculated for a test of the null hypothesis
H0β : βp1 = · · · = βpm, which addresses the question of whether each risk factor has the same
effect across all subtypes of disease. Traditional logistic regression models are additionally
fit for each subtype separately versus the controls, allowing for incorporation of the offset
terms required to correct for the original sampling design used in CBCS in order to obtain
interpretable and generalizable odds ratio estimates. More details of the need for offset
terms follow in Section 4.2.5.
4.2.4 Identifying the ideal number of classes
After identifying the optimal 2-class, 3-class, 4-class, and 5-class solutions in the discovery
stage, permutation tests were used to test whether the optimal D∗ for each class size carries
a significant heterogeneity signal. To conduct the permutation tests, for each class size
the unique k-means clustering solutions from the 1000 random starts are retained. Then
the rows of the candidate class solutions are permuted so that the class label is rendered
independent of the risk factor data, D∗ is re-calculated for each candidate solution, and the
solution that maximizes D∗ is selected. This process is repeated 1000 times to obtain a null
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reference distribution for D∗ for each class size. The p-value is calculated as the proportion
of times the observed optimal D∗ is less than the optimal D∗ obtained from the permuted
data, and serves as a test of H0 : D
∗ = 0, i.e. a test of the hypothesis that none of the risk
factors have differing effects across the classes. Failure to reject this null hypothesis implies
that the candidate discovery class solution did not demonstrate etiologic heterogeneity with
respect to the risk factors included in this analysis. Any candidate discovery class solution
that results in a failure to reject this null hypothesis was not considered further.
Next the ideal number of classes must be selected from among the candidate discovery
class solutions that demonstrate significant etiologic heterogeneity. To do so, the process of
ranking the genes to obtain a reduced set and identifying the optimal solutions of different
sizes is repeated in the phases 1 and 2 data, as described in Section 4.2.3. The two resulting
2-class, 3-class, 4-class, and 5-class validation class solutions are cross-tabulated with the
discovery class solutions. The alignment of the two sets of class labels is used to select the
ideal number of classes.
4.2.5 Additional methodologic considerations
Because black and young breast cancer cases were oversampled in CBCS, it is necessary to
make some adjustments to the statistical analyses to account for this study design. Sampling
weights were defined as the inverse of the sampling probability, and are required for inference
to the general population. Offset terms were defined as the natural log of the ratio of
the sampling probability for a case in a specific stratum of age and race to the sampling
probability for a control in the same stratum of age and race, and are required to obtain
valid odds ratio estimates. Polytomous logistic regression does not allow for incorporation
of offset terms, so polytomous logistic regression will be utilized in identification of the
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optimal subtype solution, and to conduct statistical tests of the null hypothesis that risk
factor effects are the same across the subtypes. Individual binary logistic regression models
comparing each subtype to all controls, and incorporating the offset term, will be used to
obtain corrected odds ratios.
4.2.6 Sensitivity analyses
To examine the reliability of the primary results, a number of sensitivity analyses are con-
ducted. The first is to assess the presumption that similar gene rankings would be obtained
using the case-only D∗ value and the case-control D value. In the primary analysis, the
original design of the CBCS study was used to split the data into a discovery stage that
included the phase 3 cases and a validation stage that included the phases 1 and 2 cases
and controls. Because CBCS phase 3 was a case-only design, a case-only design was used in
the discovery stage, where one subtype was used as the reference group in the polytomous
logistic regression model to calculate D∗ as described in Section 4.2.1. CBCS phases 1
and 2 included controls who were frequency matched to cases, allowing for calculation of
D using a case-control design in the validation stage. By ranking the genes and obtaining
the optimal subtype solutions using D∗ in the discovery stage, and then applying the class
labels to the validation cases, it is presumed that the results of a case-only approach are
applicable to a case-control setting. This presumption is examined in two ways, with the
goal of showing that similar gene rankings would be obtained using either a case-only or
case-control design. First, a random sample of the phases 1 and 2 controls is obtained to
use as an unmatched control sample for the phase 3 cases, and the genes are re-ranked
according to their individual case-control D values calculated in the phase 3 cases and this
random sample of phases 1 and 2 controls. This ranking is compared to the primary ranking
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obtained using the individual gene case-only D∗ values based on the phase 3 cases. Second,
the genes are re-ranked according to their individual case-only D∗ values calculated in the
phases 1 and 2 cases. This ranking is compared to the primary ranking obtained using the
individual gene case-control D values calculated in the phases 1 and 2 cases and controls.
This allows for assessment of the sensitivity of the method to the use of case-only D∗ in
the discovery stage and case-control D in the validation stage to obtain rankings for the
individual genes. Because the primary goal of this sensitivity analysis is to compare rank-
ings of individual genes according to different approaches for quantifying heterogeneity, the
individual gene etiologic heterogeneity measures have not been adjusted for correlation.
A second sensitivity analysis assesses the impact of adjusting the selection of included
genes for correlation. Some subsets of genes included in the study are known to be highly
correlated. Therefore adjustment for correlation was used to avoid a situation where many
genes carrying a similar heterogeneity signal were selected for inclusion, thus eliminating
other genes that could provide more independent information. To examine the impact
of this adjustment for correlation, with the goal of assessing whether a more etiologically
heterogeneous solution can truly be identified based on selecting a more independent set
of genes for inclusion in the clustering, the top 40 genes ranked by their individual D∗
values in the discovery data, without adjustment for correlation, are used in clustering
as described in Section 4.2.1. Validation D values based on these clustering results are
calculated as described in Section 4.2.3 for the primary results, and the alignment of the
class results based on the selected genes accounting for correlation and the selected genes
not accounting for correlation is compared.
The third sensitivity analysis assesses whether the level of variable selection, which was
somewhat arbitrarily set at 10% of the overall gene list, was sufficiently strict. Simulation
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studies presented in Chapter 3 revealed that problems of “counterfeit” structure and noise
in the data can be overcome through pre-clustering selection of tumor marker data, so the
goal of this sensitivity analysis is to try to assess whether the selection was sufficiently
stringent, or if more etiologically heterogeneous solutions could be identified with further
selection. To examine the impact of more stringent variable selection, the number of genes
included in the analysis is systematically reduced. In the discovery cases, beginning with the
list of 40 genes ranked from highest to lowest based on their individual D∗ values adjusted
for correlation, genes are removed from the bottom of the list one at a time. Each time
a gene is removed the remaining genes are used in clustering as described in Section 4.2.1
to identify the optimal solution for the various class sizes. The validation cases are then
assigned to these optimal classes based on different numbers of included genes as described
in Section 4.2.3. The resulting subtype solutions based on different numbers of genes are
compared according to their D values, as well as the alignment between discovery and
validation class labels.
The etiologic heterogeneity of breast cancer has been examined in a previous study using
gene expression data from the Cancer and Stereoid Hormone (CASH) case-control study
(Begg et al., 2015), and the final sensitivity analysis compares the rankings of common
genes between the CASH and CBCS studies. The CASH study was a case-control study of
breast cancer that assessed a panel of 202 gene expression values on the cases. Using the
same risk factors as in the primary analysis of the CBCS data, D values are calculated for
the individual genes in CASH. For the 38 genes that are in common between the CASH and
CBCS studies, the rankings are obtained according to etiologic heterogeneity as measured
in the CBCS phases 1 and 2 case-control study and the CASH case-control study. The goal
is to determine whether any genes are commonly ranked highly across the two independent
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Figure 4.2: Comparison of gene expression distributions in 20 held-out samples from phase
3 and 20 held-out samples from phases 1 and 2
studies, and as such the rankings in this sensitivity analysis have not been adjusted for
correlation since interest is not in identifying a reduced gene set.
4.2.7 Software
All statistical analyses in this chapter were conducted using R software (R Core Team, 2018).
An R package containing functions to perform specific calculations related to calculation
of D and etiologic hetereogeneity p-values is available on GitHub at https://github.com/
zabore/riskclustr.
4.3 Results
Figure 4.2 shows the distributions of gene expression values for the 20 held-out samples from
phase 3 and the 20 held-out samples from phases 1 and 2, which do not differ significantly
(p-value = 0.295). As a result, the discovery and validation cases can be combined to
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obtain the 2-class splits for each gene, since expression levels are similarly distributed.
Differences in risk factor distributions between the discovery and validation case sets are
tested using the full case population (Table 4.1). Validation cases have significantly younger
age at first birth, lighter premenopausal and postmenopausal body mass index (BMI),
lower frequency of nulliparity, lower frequency of ever oral contraceptive use, and are less
frequently black as compared to the discovery cases. However these differences should not
impact the primary analyses as some were invoked by the design of the study and interest
is in relative measures of risk for breast cancer. Note that the frequencies presented in
Table 4.1 are not generalizable to the population as a whole, but rather represent descriptive
information about the study sample, as sampling weights have not been taken into account
in these calculations.
Before beginning an investigation of subtypes in these data, it is of interest to examine
the overall case-control odds ratios for the risk factors using logistic regression with the
offset term incorporated to account for the oversampling in the study design, using the
validation cases and controls from phases 1 and 2. Table 4.2 shows that increased age
at diagnosis, first degree family history of breast cancer, and black versus white race are
significantly associated with increased odds of breast cancer in this population. Increased
postmenopausal BMI is significantly associated with decreased odds of breast cancer. The
other risk factors have been implicated in other studies in the literature, though their
effects in the CBCS data are small and not statistically significant (Huang et al., 2000).
It is possible that the sampling design of CBCS, which oversampled black women and
women < 50 years old, could have led to distributions of hormonal risk factors that are not
representative of the general population, thus obscuring common associations with risk for
breast cancer.
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Table 4.1: Comparison of risk factor distributions between the discovery and validation case
sets. Numbers presented are median (minimum, maximum) for continuous variables and
frequency (percent) for binary variables.
Variable Discovery (n = 467) Validation (n = 370) p-value
Age at diagnosis 49 (23, 74) 49 (23, 73) 0.77
Age at menarche 12 (8, 18) 13 (8, 21) 0.07
Age at 1st birth 23.5 (13, 44) 22.4 (14, 39) 0.001
Months breastfeeding 0 (0, 95) 0 (0, 58) 0.11
Premenopausal BMI† 30 (17.7, 62.5) 29.1 (15.1, 53) <.001
Postmenopausal BMI† 31.2 (17.7, 51.4) 29.7 (14.3, 53.5) <.001
Nulliparous 88 (18.8) 50 (13.5) 0.04
Postmenopausal 233 (49.9) 188 (50.8) 0.83
Ever use of OCs‡ 372 (79.7) 250 (67.6) <.001
Family history* 84 (18) 64 (17.3) 0.86
Black race 275 (58.9) 179 (48.4) 0.003
†BMI = body mass index
‡OC = oral contraceptive
*First degree family history of breast cancer
4.3.1 Discovery results
First, in Figure 4.3 the correlation among the top 40 genes based on ranking the genes
according to their individual D∗ values (Figure 4.3A) is compared to the correlation among
the top 40 genes based on ranking the genes with adjustment for correlation (Figure 4.3B).
The correlation among the top genes was very strong, but after weighting D for correlation
and re-ranking the genes, a set of genes that carry more independent information is selected.
These top 40 genes, along with their individual D∗ values, are listed in Table 4.3. PSPHL
is the top-ranked gene, with a D∗ value of 0.285. Note that some genes known to play a
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Table 4.2: Overall case-control logistic regression results in validation data. Additionally
adjusted for study phase. OR = odds ratio; CI = confidence interval.
Variable OR (95% CI) p-value
Age at diagnosis (per 10 years) 1.68 (1.41 - 1.99) <.001
Age at menarche (per 2 years) 0.91 (0.78 - 1.06) 0.21
Age at 1st birth (per 5 years) 1.06 (0.93 - 1.20) 0.40
Months breastfeeding (per 6) 0.95 (0.87 - 1.02) 0.17
Premenopausal BMI† (per 20 units) 0.90 (0.56 - 1.46) 0.67
Postmenopausal BMI† (per 20 units) 0.45 (0.27 - 0.77) 0.004
Nulliparous 1.03 (0.71 - 1.49) 0.88
Postmenopausal 1.08 (0.74 - 1.58) 0.69
Ever use of OCs‡ 1.17 (0.87 - 1.57) 0.31
Family history* 1.53 (1.11 - 2.13) 0.01
Black vs white 1.31 (1.00 - 1.71) 0.046
†BMI = body mass index
‡OC = oral contraceptive
*First degree family history of breast cancer
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Figure 4.3: Heatmaps of correlation among the top 40 genes in the discovery data (A) based
on ranking the genes using their individual D∗ values and (B) based on ranking the genes
with adjustment for correlation.
role in subtyping breast cancer, including ESR1 with a D∗ value of 0.119 and SCUBE2
with a D∗ value of 0.100, are not included in the list of selected genes after accounting for
correlation, as they were strongly correlated with the top-ranked gene. Next the selected 40
genes are clustered using the original continuous data, and for each class size the candidate
solution that maximizes D∗ is selected as the optimal solution. The true optimal D∗ value
is signficantly greater than the null reference distribution for all class sizes, as indicated by
the purple asterisks denoting the observed optimal D∗ lying far from the null distribution
of D∗ (Figure 4.4) and by the significant permutation-based p-values (Table 4.4).
Next the ideal number of classes to use in the remaining analyses is determined by
examining the alignment between the optimal solutions identified using the discovery phase
3 data and the optimal solutions identified independently using the validation data from
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Table 4.3: Top 40 genes in the discovery data, selected by ranking genes according to D∗
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Figure 4.4: Histograms of the null reference distributions of D∗ for each class size in the
discovery data. The purple asterisk denotes the observed optimal D∗ values.
Table 4.4: Optimal D∗ in the discovery data for each class size, with permutation-based
p-values.
Number of classes D∗ p-value
2 0.154 < .001
3 0.248 < .001
4 0.303 < .001
5 0.348 < .001
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Figure 4.5: Alignment over benchmark level between optimal class labels identified inde-
pendently in the phase 3 and phases 1 and 2 data, by class size.
phases 1 and 2, as described in Section 4.2.4. The alignment is calculated by cross-tabulating
the two sets of class labels for each class size and then obtaining the proportion of cases on
the diagonal. Since class labels from k-means clustering are arbitrary, the two sets of class
labels must first be aligned, as desribed in Section 3.2.4 of Chapter 3. Additionally, because
it is easier to achieve alignment when there are fewer classes, a benchmark level of alignment
is established for each class size based on the sum of the squared relative frequencies of the
discovery classes. Figure 4.5 shows the amount of additional alignment achieved above
the benchmark level, and indicates that the 4-class solution achieves the highest level of
additional alignment. This strong alignment combined with the fact that the traditional
IHC and PAM50 4-class solutions are already well-accepted in breast cancer, the 4-class
solution is selected for use in the validation stage of this analysis. In the discovery data
there are 114 (24.4%) cases in subtype 1, 174 (37.3%) cases in subtype 2, 135 (28.9%) cases
in subtype 3, and 44 (9.4%) cases in subtype 4.
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4.3.2 Validation results
Each validation case from the phase 1 and 2 data is assigned to its subtype based on the
4-class discovery solution as described in Section 4.2.3. There are 84 (22.7%) cases assigned
to subtype 1, 110 (29.7%) cases assigned to subtype 2, 107 (28.9%) cases assigned to subtype
3, and 69 (18.6%) cases assigned to subtype 4. The high alignment of 66% between the
4-class solutions identified independently in the phase 3 and phases 1 and 2 cases indicates
that the subtypes are reasonably replicable (Table 4.5).
Table 4.5: Alignment between the optimal discovery 4-class solution and the optimal vali-
dation 4-class solution, in the validation cases.
Validation 4-class
Discovery 4-class 1 2 3 4
1 74 0 11 12
4 0 60 26 7
2 7 46 66 6
3 3 4 4 44
The D value for the optimal discovery 4-class solution in the validation cases is 0.271.
Table 4.6 shows the alignment between the traditional 4-class subtyping system based on
three IHC markers (ER, PR, and HER2) and the optimal 4-class solution. 52.5% of cases are
classified similarly according to the two subtyping schemes. The D value for the traditional
IHC 4-class system is 0.165, which is much lower than the D value of 0.271 for the optimal
4-class solution. Similarly, Table 4.7 shows the alignment between the traditional 4-class
subtyping system based on the PAM50 gene expression panel and the optimal validation 4-
class solution. 60.2% of cases are classified similarly according to the two subtyping schemes.
The D value for the traditional PAM50 4-class system is 0.153, which again is much lower
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Table 4.6: Cross-tabulation of traditional 4-class subtypes based on IHC markers and op-
timal 4-class solution in phase 1 and 2 cases. Note that 10 cases are missing values for the
traditional IHC 4-class solution.
Optimal 4-class
Traditional IHC 4-class 1 2 3 4
Triple negative 68 7 17 21
Luminal A 13 95 47 39
HER2-type 1 1 21 1
Luminal B 0 3 21 5
than the D value of 0.271 for the optimal 4-class solution. These results suggest that
while the optimal 4-class solution is fairly well-aligned with the more traditional 4-class
subtyping solutions, the most etiologically heterogeneous subtyping solution had not yet
been defined, as the identified optimal solution demonstrates a substantially larger etiologic
heterogeneity signal. It is of interest to note that optimal class 1 is particularly well aligned
with the triple negative and basal-like subtypes, and optimal class 2 is quite strongly aligned
with the luminal A subtype.
Table 4.7: Cross-tabulation of traditional 4-class subtypes based on the PAM50 gene ex-
pression panel and optimal 4-class solution in phase 1 and 2 cases. Note that 26 cases
classified as normal-like by the traditional PAM50 solution are excluded.
Optimal 4-class
Traditional PAM50 4-class 1 2 3 4
Basal-like 79 0 7 43
Luminal A 1 93 43 15
HER2-type 1 0 32 2
Luminal B 3 4 18 3
Next the univariable associations between the risk factors of interest and the optimal
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Table 4.8: Risk factor distributions in phase 1 and 2 cases according to the optimal 4-class
solution. Numbers presented are median (minimum, maximum) for continuous variables
and frequency (percent) for binary variables.
Optimal 4-class
Variable 1 (n = 84) 2 (n = 110) 3 (n = 107) 4 (n = 69) p-value
Age at diagnosis 45 (24, 73) 53 (24, 73) 49 (27, 73) 50 (23, 73) <.001
Age at menarche 12 (9, 16) 13 (8, 18) 13 (9, 21) 13 (9, 16) 0.13
Age at 1st birth 20 (14, 36) 22.4 (14, 35) 22.4 (14, 39) 22 (14, 36) 0.14
Months breastfeeding 0 (0, 58) 0 (0, 54) 0 (0, 31) 0 (0, 58) 0.18
Premenopausal BMI† 29 (18, 47) 29 (20, 53) 29 (15, 46) 29 (18, 53) 0.44
Postmenopausal BMI† 30 (18, 48) 30 (14, 49) 30 (18, 53) 29 (18, 33) <.001
Nulliparous 8 (9.5) 17 (15.5) 18 (16.8) 7 (10.1) 0.37
Postmenopausal 28 (33.3) 64 (58.2) 54 (50.5) 42 (60.9) 0.001
Ever use of OCs‡ 63 (75) 73 (66.4) 64 (59.8) 50 (72.5) 0.12
Family history* 14 (16.7) 21 (19.1) 18 (16.8) 11 (15.9) 0.95
Black race 54 (64.3) 42 (38.2) 56 (52.3) 27 (39.1) 0.001
†BMI = body mass index
‡OC = oral contraceptive
*First degree family history of breast cancer
4-class solution are presented in Table 4.8. Note that these results are not generalizable to
the population as a whole, but rather represent descriptive information about the included
study sample, as sampling weights have not been taken into account in these calculations.
Age at diagnosis, postmenopausal BMI, postmenopausal status, and race are all significantly
associated with the optimal 4-class solution on univariable analysis. Cases in optimal class
1 appear to be younger, less frequently postmenopausal, and more frequently black. Cases
in optimal class 2 appear to be older, more frequently postmenopausal, and more frequently
white. Odds ratios and 95% confidence intervals from multivariable logistic regression mod-
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els separately comparing each optimal class to the controls, and accounting for offset terms,
are shown in Figure 4.6. The p-values on the plot are from the test for heterogeneity based
on a multivariable polytomous logistic regression model, as described in Section 4.2.3. Age
at diagnosis, postmenopausal BMI, ever use of oral contraceptives, and race all demonstrate
significant heterogeneity across the four subtypes in multivariable analysis. Older women
have increased odds of class 2 breast cancer, women with higher postmenopausal BMI have
decreased odds of class 4 breast cancer, women who ever used oral contraceptives have
decreased odds of class 3 breast cancer, and black women have increased odds of class 1
breast cancer and decreased odds of class 2 breast cancer.
A heatmap of expression values for the 40 included genes according to the optimal 4-
class solution in the validation cases is shown in Figure 4.7. Optimal class 4 tends to have
lower expression levels, especially for PSPHL, a gene with known race associations (Parada
et al., 2017). Recall that class 4 has a lower frequency of black women, and PSPHL is
known to be more highly expressed in black women. Notably, optimal class 3 has higher
expression of ERBB2, the gene that represents human epidermal growth factor receptor 2
(HER2). Tables 4.6 and 4.7 had previously indicated that HER2-type cancers were almost
exclusively classified into optimal class 3.
4.3.3 Sensitivity to use of case-only data to identify subtypes
Because phase 3 of CBCS did not include frequency matched controls, the subtypes in the
discovery stage of this analysis were identified in a case-only setting. The phases 1 and 2
cases were then assigned to a discovery class, and risk factor associations were tested in a
case-control context. To address this design difference between the discovery and validation
stages, a sensitivity analysis is conducted to assess the presumption that similar rankings
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Figure 4.6: Odds ratios and 95% confidence intervals from multivariable binary logistic
regression with offset term incorporated, in the validation data. Additionally adjusted for
study phase. P -values are tests for etiologic heterogeneity from a multivariable polytomous
logistic regression model. OR = odds ratio; CI = confidence interval.
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Figure 4.7: Heatmap of expression values for the selected 40 genes according to the optimal
4-class solution in the validation data.
Table 4.9: Comparison of rankings according to case-only D∗ in the phase 3 cases, and
case-control D in the phase 3 cases and a random sample of phases 1 and 2 controls.
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would be obtained in a case-only or case-control setting. First, rankings are compared
based on individual gene D∗ values calculated in the phase 3 cases only versus individual
gene D values calculated in the phase 3 cases and a random sample of the phases 1 and 2
control subjects. All 40 of the top 40 genes overlap according to the two rankings, and more
specifically, the top-ranked gene is PSPHL according to both rankings and 9 of the top 10
genes are the same between the two rankings (Table 4.9). Next, rankings are compared
based on individual gene D values calculated in the phases 1 and 2 cases and controls
versus individual gene D∗ values calculated in the phases 1 and 2 cases only. Thirty-seven
of the top 40 genes overlap according to the two rankings, and more specifically, PSPHL
is again the top-ranked gene according to both rankings, and in both rankings SLC7A5 is
the 2nd ranked gene and ESR1 is the 3rd ranked gene, and 8 of the top 10 genes are the
same according to the two rankings (Table 4.10). These results support the use of D∗ in the
discovery stage and D in the validation stage, and suggest that the obtained rankings would
be similar even if a case-only approach or case-control approach had been consistently used
across the two stages of analysis.
4.3.4 Sensitivity to gene selection adjusting for correlation
As some of the genes included in the CBCS codeset were known to be highly correlated,
an adjustment for correlation was used when ranking the genes in the primary analysis. A
second sensitivity analysis was conducted to assess the impact of accounting for correlation
among genes when selecting the top-ranked genes for inclusion in clustering. Table 4.11
shows that the optimal 4-class solution in the validation data based on clustering the top
40 genes ranked by individual D∗ ignoring correlation has 62% alignment with the optimal
4-class solution in the validation data based on clustering the top 40 genes after adjusting
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Table 4.10: Comparison of rankings according to case-control D in the phases 1 and 2 cases
and controls, and case-only D∗ in the phases 1 and 2 cases.











individualD∗ values for correlation. Encouragingly, the validationD of 0.271 for the optimal
4-class solution from the primary results surpasses the D of 0.221 for the optimal 4-class
solution based on clustering the top 40 genes selected without adjustment for correlation,
suggesting that more risk heterogeneity signal is picked up by selecting a more independent
set of genes for inclusion in clustering.
Table 4.11: Cross-tabulation of validation optimal 4-class solutions when correlation is
considered or not in selecting the top 40 genes.
Optimal 4-class
Ignoring correlation 1 2 3 4
1 66 0 3 2
2 0 83 15 17
3 1 27 53 23
4 17 0 36 27
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4.3.5 Sensitivity to level of variable selection
In the primary analysis a set of 40 genes, representing the top 10% of genes, were selected
for inclusion in the clustering. Next a sensitivity analysis to examine the impact of the
extent of variable selection on the results is conducted, as described in Section 4.2.6. As
shown in Figure 4.8, there are a number of 4-class solutions with higher D values than the
primary 4-class solution based on 40 genes, and the maximum D value of 0.395 is achieved
when only the top 12 genes are included. When the top 40 genes are identified separately
in the phase 3 discovery data and the phases 1 and 2 validation data, only 9 genes (22.5%)
are common between the two lists (Table 4.12). Reassuringly, PSPHL is the top-ranked
gene when ranking is done independently in the discovery and validation data. PGE3 is
the only other gene included in the top 10 according to both rankings. Figure 4.9 shows
the proportion of aligned cases according to class labels assigned based on the optimal
discovery 4-class solution and class labels based on the optimal 4-class solution identified
independently in the validation cases, as the number of included genes is reduced. The
proportion of aligned cases increases as the number of included genes is reduced, such that
85% of cases are classified similarly with an 8-gene or 6-gene solution, 91% of cases are
classified similarly with a 4-gene solution, and 95% of cases are classified similarly with
a 1-gene solution. These results combine to suggest that perhaps more stringent variable
selection, to just the top 8 or 6 genes, would lead to a more etiologically heterogeneous
solution with high alignment between two independent class labels, suggesting stability in
the clustering based on this small number of genes.
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Figure 4.8: D values in the validation data when different numbers of genes are included in
identification of the optimal 4-class solution.
Figure 4.9: Alignment between optimal class labels identified independently in the phase 3
and phases 1 and 2 data, as the number of included genes is reduced.
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Table 4.12: Similar genes according to discovery and validation rankings.
Gene Discovery D∗ Discovery rank Validation D Validation rank
PSPHL 0.285 1 0.228 1
PGE3 0.039 5 0.076 8
F7 0.060 11 0.063 16
FMO5 0.109 13 0.096 32
DSP 0.048 16 0.076 37
NCR1 NKP46 0.023 18 0.052 20
REPS2 0.073 27 0.088 38
SLC7A5 0.136 28 0.137 18
LOC400043 0.087 35 0.076 17
4.3.6 Comparison of gene rankings in the CBCS and CASH studies
A final sensitivity analysis compares gene rankings according to CBCS phases 1 and 2 case-
control rankings and CASH case-control rankings (Table 4.13). Of the 38 common genes
between the CBCS and CASH studies, several are consistently highly ranked, including
SLC7A5, ESR1, PGR, IL6ST, AR, GATA3, and BCL2. The Spearman correlation between
the two rankings was 0.449, a moderate correlation that differed significantly from zero
(p-value = 0.005). Interestingly only SLC7A5 remained in the top 40 selected genes in the
CBCS phase 3 discovery rankings after adjustment for correlation, as the other genes com-
mon between the two studies were all highly correlated with the top-ranked gene, PSPHL.
4.4 Discussion
In this data application a novel clustering strategy was used to identify a set of breast cancer
subtypes that have clearly distinctive etiology that surpasses that of traditional molecular
subtypes in breast cancer. Etiologic differences in these data appeared to be driven by the
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Table 4.13: Comparison of gene rankings for the 38 common genes in the CBCS phases 1
and 2 case-control study and the CASH case-control study.







































CHAPTER 4. APPLICATION TO CAROLINA BREAST CANCER STUDY 106
PSPHL gene, which was consistently ranked as the top gene across multiple approaches to
ranking, and demonstrated a high level of etiologic heterogeneity when used as an individual
gene. PSPHL is known to be associated with race, such that black women have higher
expression of PSPHL as compared to white women (Parada et al., 2017; Costantino et al.,
2016; Field et al., 2012), and there were clear differences in PSPHL across subtypes in
this study. ESR1 and PGR were two of the genes identified in the top 10 of the common
genes between the CBCS and CASH studies, and these encode estrogen receptor (ER) and
progesterone receptor (PR), which are both known to play a role in breast cancer risk and
in determining subtypes of breast cancer. ER and PR help form the traditional IHC 4-class
subtype solution and similarly ESR1 and PGR are part of the PAM50 gene expression panel
that forms the basis of the traditional PAM50 4-class subtype solution. Similarly, ERBB2
is the gene that encodes human epidermal growth factor receptor 2 (HER2), and was the
2nd-ranked gene in this study after adjustment for correlation. HER2 is also involved in
formation of the traditional IHC 4-class subtype solution and, correspondingly, ERBB2 is
included in the PAM50 gene expression panel.
One gene that is thought to play an important role in breast cancer but was not consid-
ered in the primary results of this analysis is TP53. While not emphasized in the primary
results, in the validation cases the 2-class solution based on a TP53 multigene signature
has a D value of 0.029. This would lead to a ranking of 345/407 individual genes, when
no adjustment is made for correlation. Because RNA expression of the TP53 gene is not
believed to capture the biologic mechanism through which TP53 acts in breast cancer, it
is therefore not recommended for analysis as a single gene in a study of this type. Instead,
a multigene signature for TP53 is used, and each case is assigned to a “mutant” or “wild-
type” class based on a principal components analysis of the multigene signature. While
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this multigene signature for TP53 does not appear to contribute strongly to distinguishing
etiologically heterogeneous subtypes when considered alone in these data, it is possible that
it could be important when considered together with other genes, and future work should
determine how best to incorporate this type of information that is on a different scale (i.e.
binary versus continuous) into the novel clustering strategy.
Risk factors that contributed the most to distinguishing the optimal 4-class solution
included age at diagnosis, postmenopausal BMI, ever use of oral contraceptives, and race.
In a pooled analysis across multiple cohort studies, Gaudet et al. (2018) found that parity,
age at first live birth, years between menarche and first birth among parous women, age at
menopause, and first degree family history of breast cancer were risk factors that demon-
strated etiologic heterogeneity according to the traditional IHC 4-class subtypes. Race was
not included in their analysis. Interestingly, none of these risk factors are the ones that
demonstrated etiologic heterogeneity according to the optimal 4-class solution in this anal-
ysis. This could be an artifact of the somewhat artificial risk factor distributions in the
CBCS study population, induced as a result of the study design that oversampled black
women and young women. Alternatively, the differences could be caused by shifting risk
factor distributions over time, especially with respect to hormonal risk factors, and changes
in the way immunohistochemical markers have been categorized as positive or negative.
There are some remaining methodologic challenges. The first challenge is how to deter-
mine the number of tumor markers to include in the clustering analysis. In this application
the top 10% were selected based on their individual measures of etiologic heterogeneity, and
thus 40 genes were clustered. However, sensitivity analyses indicated that solutions based
on even fewer genes led to higher measures of explained variation, as well as better alignment
between optimal class solutions identified in two independent datasets. This suggests that
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the ideal solution in these data may be based on only 8 or 6 genes, rather than the 40 used
in the primary analysis. A more objective approach to determining a cutoff for inclusion is
needed to determine the appropriate level of upfront variable selection. A second challenge
is how to select the ideal number of subtypes. In any unsupervised clustering analysis, the
number of classes must be pre-specified, though the true number of underlying classes of
interest is unknown. In this data example 2-class, 3-class, 4-class, and 5-class solutions
were compared. Solutions with more than five classes were not considered to avoid model
overfitting given the number of available cases. However the approach used to select the
4-class solution as ideal, based on the alignment between solutions from two independent
datasets as well as permutation tests for significant differences in the amount of explained
variation, was somewhat arbitrary. Additionally, the 4-class solution was selected in part
based on the knowledge that there are existing 4-class breast cancer subtyping schemes, and
so using four classes would make comparisons with these other classification systems easier.
More rigorous and objective methods to select the ideal number of classes in an analysis of
etiologic heterogeneity are needed, and this will be an area of future work.
Overall, this data application demonstrates that when the proposed novel clustering
strategy is used, which combines a search for candidate subtypes with a measure of etiologic
heterogeneity based on the available risk factor data, subtype solutions with higher levels of
etiologic heterogeneity can be discovered. This is important for epidemiologists who seek to
identify solutions that maximize risk heterogeneity across subtypes. While components of
this analysis are still subjective, this is in line with the real challenges faced when conducting
complex real-world epidemiologic studies, and is therefore not a major limitation.
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4.5 Gene expression panel
ABAT F7 OCLN ADM KRT14
ABCB1 FAM54A PCSK6 AMH KRT17
ABCC8 FAM63A PD L1 AMHR2 KRT19
ACADSB FAM64A PDCD1 ANGPTL4 KRT5
ACTG1P3 FANCA PDSS1 ANLN KRT8
ADCY1 FBXL6 PDZK1 APH1B LEPRE1
AKR7L FCRL2 PFKP ATAD2 LHFP
ALDH1A1 FLJ20152 PGAM5 AURKA LOC400043
APBB2 FMNL2 PGE3 AXL MAD2L1
AQP5 FMO5 PINK1 BAG1 MAP2K4
AR FN1 PKIB BCL2 MAPT
AURKB FOXC2 PLK1 BIRC5 MCM3
BLK FOXP3 PPBP BLVRA MDM2
BLR1 CXCR5 FPRL1 PRF1 BRCA1 MELK
BMP2 FSCN1 PRRG2 BTG2 MET
BOP1 FUT8 PRRT2 CAV1 MIA
BTG3 GALT PTDSS1 MIS18A C21ORF45 CCNA2
BUB1 GCNT2 PTGER3 CCNB1 MKI67
C10ORF116 GFRA1 PTGS2 CCND1 MLPH
C11ORF75 GPR44 PTPRT CCNE1 MMP11
C14ORF45 GTSE1 PUF60 CD24 MPP1
C16ORF45 GUCA1 PVRL2 CDC20 MSH3
C1QTNF3 GZMM RAD54L CDC25B MUC1
C1ORF106 HGH1 RAI2 CDC25C MYBL2
C2ORF27A HJURP RBM24 CDC6 MYC
C4A HLA DOB REEP6 CDCA7L NAT1
C4ORF31 HPN REPS2 CDH3 NCAPH2
C8ORF33 HRC RIMS4 CDK1 NDC80
C9ORF98 ICOS RNASE4 CDKN1A NDRG1
CACNB3 IDO1 RPS6KB2 CDKN3 NEO1
CALCP IFRD1 RSPH1 CENPF NPEPPS
CAPN13 IGF2BP2 S100A8 CEP55 NT5E
CAPN9 IGF2BP3 SCGB1D2 CKS1B NUDT1
CASKIN1 IL12 SCUBE2 CLDN3 NUF2
CCDC103 IL1B SDCBP CLDN4 ORC6L
CCL7 IL2RB SEC14L2 CLDN7 PGR
CCNB2 IL5RA SEMA3B CRMP1 PHGDH
CCR3 IL6 SERPINB5 MASPIN CRYAB PIK3CA
CD10 IL6ST SH2D1A CRYBB2 PLOD1
CD19 IL8RA SHCBP1 CXXC5 PNP
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CD2 IL8RB SHROOM3 DAPK1 POLD1
CD246 CD3Z INPP4B SIRPG DDB2 PREP
CD28 IRS1 SKAP1 DDIT4 PSPH
CD3E ISLR2 SLC1A2 DDR1 PSPHL
CD3G ITGB5 SLC52A2 DSP PTEN
CD4 KCNMA1 SLC7A5 EGFR PTTG1
CD6 KCNN4 SNAI1 EMP3 PVRL3
CD68 KDM4B SNAI2 EPCAM RAB25
CD84 KIAA0125 SNRPD1 ERBB2 RAD17
CD8A KIF3A SOX10 ERBB3 RAD50
CD96 KLHDC9 STC2 ERBB4 RB1
CDC45 KLHL7 SULT1E1 ESR1 RFC4
CDCA5 LAG 3 SULT2A1 ESRP1 RNF103
CDCA7 LCK SYBU EVI2A RRAGD
CDCA8 LILRB2 SYT1 EXO1 RRM2
CDH1 LOX TBC1D9 F11R SFRP1
CELSR1 LRG1 TFF3 FABP5 SH2B3
CENPA LRP8 TIM 3 FAM177A1 SLC16A3
CENPN LRRC50 TMSB15B FAM198B SLC39A6
CMC2 MAF TNFRSF17 FAM214A KIAA1370 SPINT1
CMYA5 MAGED2 TPX2 FBN1 SPINT2
CTSL2 MAGI2 TRAF1 FGFR4 SQLE
CXCL13 MARVELD2 TRAT1 FLVCR2 STK38
CXCL5 MCM10 TRPC1 FNBP1 TCEAL1
CXCR4 MMP1 TRPM7 FOXA1 TMEM158
CYBB MMP2 TWIEST2 FOXC1 TMEM45B
CYP19A1 MMP3 TWIST1 FOXM1 TNIK
CYP27A1 MND1 UGT1A10 GAL TOP2A
CYP2D6 MRPS17 UGT1A4 GATA3 TRIP13
CYP3A4 MS4A1 UGT1A8 GGH TUBA4A
CYP3A5 MSR1 UGT2B7 GNG11 TYMS
CYP4B1 MYB VAV3 GPR160 UBE2C
CYP7B1 NCAPG WDR12 GRB7 UBE2T
DEPDC1 NCR1 NKP46 WDR19 GRHL2 UCHL1
DLGAP5 NCS1 XBP1 GSTP1 ULK1
DNM2 NFKB1 XCL1 GSTT2 VEGFA
DOCK3 NLN ZAP70 JUP VIM
DTX3 NME5 ZEB2 KIAA0040 ZEB1
ECE2 NR1H3 ZG16B KIF23
EFHD1 NTN4 ACOX2 KIF2C
ELOVL2 NXNL2 ACTR3B KIFC1
EZH2 NXPH4 ADHFE1 KIT
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Chapter 5
Conclusion
This dissertation investigated statistical methods related to the study of etiologic hetero-
geneity. Disease subtyping is increasing in importance, especially in cancer research, due
to the rising use of molecular and genomic profiling as part of standard patient care. As a
result, statistical methods are needed to identify risk factors that have a differential effect
across subtypes of disease, when subtypes may be formed from high dimensional disease
characteristic data.
After reviewing existing methods for the study of etiologic heterogeneity, regression-
based methods that rely on pre-specified subtypes of disease were compared, including
polytomous logistic regression, the two-stage meta-regression method of Wang et al. (2015),
the two-stage regression with simultaneous estimation method of Chatterjee (2004), and the
stratified logistic regression method of Rosner et al. (2013). The primary challenge to this
was unifying the notation of the various methods so that the similarities and differences
could be examined. After doing so it became clear that the methods can all estimate similar
parameters {βpm} to address the question of whether a risk factor of interest has the same
effect across all subtypes of disease, and similar parameters {γpk} to address the question
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of whether risk factor effects differ across levels of each individual disease characteristic
by which the subtypes are defined. A simplified data example showed that the methods
result in similar parameter estimates and conclusions, and simulation studies found that
while the stratified logistic regression method of Rosner et al. (2013) results in substantial
bias in parameter estimation for addressing whether risk factor effects differ across levels of
the disease subtype, all methods have similar power to address both questions of interest.
These results indicate that polytomous logistic regression, which is easy to implement with
standard software, performs at least as well as more complex methods and therefore is an
acceptable approach to the study of etiologic heterogeneity when data arise from a case-
control study. These results can serve to guide epidemiologists and other researchers seeking
to study etiologic heterogeneity in selection of an appropriate statistical method.
Next, the statistical properties of a novel clustering method were examined. Optimal D
clustering seeks to identify, from high dimensional disease characteristic data, the subtypes
that maximize etiologic heterogeneity. The method is conducted in two stages. In the first
stage, the disease characteristic data are clustered using unsupervised k-means clustering
with many random starts so that a variety of candidate sets of subtype solutions are found.
Then for each candidate solution, a scalar measure of etiologic heterogeneity, denoted D,
is calculated based on risk predictions from a polytomous logistic regression model with
the candidate class solution as the outcome and the known risk factors as predictors. The
subtype solution that maximizes D is selected as the optimal class solution. This approach
had been used previously in several applications, including to breast cancer (Begg et al.,
2015), melanoma (Mauguen et al., 2017), and kidney cancer (Begg et al., 2014), but this
was the first time the statistical properties had been evaluated in detail. Simplified simu-
lation studies found that the method cannot identify the truly etiologically heterogeneous
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subtype solution when the strength of counterfeit structure surpasses the strength of the
truly etiologically heterogeneous structure, or when the number of disease characteristics
representing noise is very large. However, this can be overcome with up-front reduction of
the set of disease characteristics included in the clustering, selecting the subset of charac-
teristics that show strong heterogeneity signals individually, after which the etiologically
distinct subtypes can successfully be identified with high probability.
Finally, the optimal D clustering approach was applied to data from the Carolina Breast
Cancer study. The available gene expression data was reduced up-front based on individual
gene D values, and only the top 10% of genes according to their individual contributions to
risk heterogeneity were included in the clustering, after an adjustment for correlation among
genes was applied. A 4-class solution was identified, which contained disease subtypes that
are significantly different with respect to the effects of age at diagnosis, postmenopausal
BMI, ever use of oral contraceptives, and race. PSPHL, a gene with known race asso-
ciations (Parada et al., 2017), was the gene that was most significant in distinguishing
these subtypes under a variety of approaches to gene ranking. ERBB2, the gene that en-
codes HER2, was the second ranked gene in the discovery stage of the analysis. HER2 is
known to play a role in subtyping breast cancer. The optimal 4-class solution identified in
this application demonstrated a much larger degree of etiologic heterogeneity, as quantified
by D, as compared to that seen in the traditional IHC 4-class solution or the traditional
PAM50 4-class solution. This result indicates that optimal D clustering can identify more
heterogeneous class solutions than existing breast cancer subtypes.
While this work has contributed to understanding the appropriate uses of available
statistical methods for the study of etiologic heterogeneity, there are some needed areas
of future work. The first relates to the extent of up-front disease characteristic selection.
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In the simulation studies disease characteristics were included based on a cut-off value for
permutation-based p-values, and in the data application genes were included based on a
fixed percentage of top-ranked genes. However, sensitivity analysis in the data application
revealed that solutions demonstrating even greater levels of etiologic heterogeneity could be
found after more stringent reduction of the gene set. An objective approach to selection of
disease characteristics for inclusion in the clustering stage of the analysis is needed. The
second area of future work relates to identification of the ideal number of classes. In any
unsupervised clustering analysis, the number of classes must be pre-specified. However,
the true number of etiologically distinct subtypes is not known in real-world applications.
Statistical methods exist to identify the ideal number of classes in traditional clustering
analyses, but they are not tailored to this application. An approach that considers both the
distance between clusters as well as information from the risk factors is needed. Finally, an
R package, referenced throughout this dissertation, is in development to make calculation
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